



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Jayasena, C., Anderson, R. A., Llahana, S., Barth, J., MacKenzie, F., Wilkes, S., Smith, N. D., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al (2022). Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. *Clinical Endocrinology*, 96(2), pp. 200-219. doi: 10.1111/cen.14633

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://city-test.eprints-hosting.org/id/eprint/27263/>

**Link to published version:** <https://doi.org/10.1111/cen.14633>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.



**TITLE PAGE**

**Article category**

Clinical guideline

**Title**

Society for Endocrinology guidelines for the treatment of male hypogonadism

**Authors**

Channa N. Jayasena<sup>1</sup>, Richard A Anderson<sup>2</sup>, Sofia Llahana<sup>3</sup>, Julian H. Barth<sup>4</sup>, Finlay MacKenzie<sup>5</sup>, Scott Wilkes<sup>6</sup>, Neil Smith<sup>7</sup>, Prasanna Sooriakumaran<sup>8</sup>, Sukhbinder Minhas<sup>9</sup>, Frederick C.W. Wu<sup>10</sup>, Jeremy Tomlinson<sup>11</sup>, Richard Quinton<sup>12</sup>

**Affiliations**

<sup>1</sup>Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London, UK

<sup>2</sup>MRC Centre for Reproductive Health, University of Edinburgh, UK

<sup>3</sup>School of Health Sciences, City, University of London, London & Department of Endocrinology& Diabetes, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK

<sup>4</sup>Specialist Laboratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>6</sup>School of Medicine, University of Sunderland, Sunderland, UK

<sup>7</sup>Patient member

<sup>8</sup>Department of Uro-oncology, UCLH NHS Foundation Trust, London & Nuffield

Department of Surgical Sciences, University of Oxford, Oxford, UK

<sup>9</sup>Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust,

London, UK

<sup>10</sup>Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences,

Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>11</sup>Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford,

UK

<sup>12</sup>Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals

NHS Foundation Trust & Translational & Clinical Research Institute, University of

Newcastle-upon-Tyne, UK

## **Corresponding authors**

Dr Channa N. Jayasena, Section of Investigative Medicine, 6<sup>th</sup> Floor Commonwealth

Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12

0NN, UK [c.jayasena@imperial.ac.uk](mailto:c.jayasena@imperial.ac.uk)

ORCID: <https://orcid.org/0000-0002-2578-8223>

Dr Richard Quinton, Endocrine Unit, Leazes Wing - Level 6, Royal Victoria Infirmary,

Queen Victoria Rd, Newcastle-upon-Tyne, NE1 4LP, UK [Richard.Quinton@ncl.ac.uk](mailto:Richard.Quinton@ncl.ac.uk)

ORCID: <https://orcid.org/0000-0002-4842-8095>

## **Conflicts of Interest Statement**

<sup>1</sup>CNJ: Speaker fees from Besins Healthcare

<sup>3</sup>SL: Speaker fees from Besins Healthcare, Pfizer UK, Ipsen Global and sponsorship for conference attendance from Bayer UK

<sup>8</sup>PS: Speaker fees from Janssen and Intuitive Surgical Inc., consultancy fees from Cambridge Medical Robotics

<sup>12</sup>RQ: Speaker fees and sponsorship for conference attendance from Bayer UK, and Speaker fee from Besins Healthcare and Sandoz UK

## **Author Declaration**

Please see “Author Declaration Form-Jayasena et al 2021” file

## **Funding Statement**

Contributors in this work receive research funding from the following:

<sup>1</sup>CNJ: National Institute for Healthcare Research (NIHR) Post-Doctoral Fellowship & Imperial NIHR Biomedical Research Centre;

<sup>1</sup>CNJ & <sup>12</sup>RQ: NIHR Health Technology Assessment (HTA) Grant;

<sup>3</sup>SL: NIHR ICA Post-Doctoral Clinical Lectureship (SL);

<sup>8</sup>PS: Prostate Cancer Foundation Young Investigator Award.

## ***Data availability statement***

Data sharing and data accessibility is not applicable to this manuscript

## **Summary**

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and variations in its diagnosis and management exist. There are several current guidelines on testosterone replacement therapy (TRT) which have been driven predominantly by single disciplines. The Society for Endocrinology commissioned this new guideline to provide all care providers with a multidisciplinary approach to treating patients with MH. This guideline has been compiled using expertise from endocrine (medical and nursing), primary care, clinical biochemistry, urology & reproductive medicine practices. These guidelines also provide a patient perspective to help clinicians best manage MH.

## **Key Words**

Hypogonadism, testosterone, libido, erectile dysfunction, guideline

**Word Count:** 9,692

## 89    **MAIN TEXT**

### 90    **Key points**

- 91    1. Testicular defects cause hypergonadotrophic hypogonadism or PH, identified by elevated  
92       serum gonadotrophin and low T concentrations. There is rarely a need for repeated  
93       venepuncture under optimal conditions to confirm the diagnosis.
- 94    2. The biochemical features of central hypogonadism may be indistinguishable from systemic  
95       disease (i.e. non-gonadal illness - NGI), sleep-deprivation, or even afternoon or post-  
96       prandial venepuncture. Contextual clinical ascertainment, appropriate conditions for blood  
97       sampling, and repeated measurements are required for diagnostic rigour.
- 98    3. Weight loss is a highly effective way for obese men with NGI to simultaneously reduce  
99       their cardio-metabolic risk and overall well-being, while increasing their testosterone  
100       levels.
- 101   4. Most patients with MH require long-term testosterone treatment. Effective self-  
102       management and optimising therapy is needed to achieve desired treatment outcomes,  
103       improve patient well-being and quality of life, and to minimise adverse effects of  
104       testosterone treatment over- or under- replacement. Clinicians should consider individual  
105       needs and preferences when discussing testosterone initiation. Clinicians should develop a  
106       tailored treatment plan in partnership with their patients considering the benefits and  
107       disadvantages of available testosterone treatment formulations individualised for each  
108       patient.
- 109   5. All patients should be provided with education about their condition and treatment aiming  
110       to improve adherence and optimisation of testosterone treatment. Clinicians should

consider individual needs and preferences when discussing testosterone treatment initiation.

6. Regardless of the aetiology of hypogonadism, sexual dysfunction and infertility can severely impact quality of life, including psychological, relationship and interpersonal issues.

## **1. Introduction and Methods**

Male Hypogonadism (MH) is defined by deficient testosterone production and impaired spermatogenesis by the testes. MH can manifest at any point in life, from puberty, adult life and through to old age, and is characterised biochemically by low circulating serum testosterone levels and clinically by a wide range of signs and symptoms of T deficiency (Table 1)<sup>1</sup>. MH has consequences for health and well-being beyond sexual function and contributes to male infertility. The actual prevalence of MH is uncertain, depending on whether estimates are based upon the diagnosis of a hypogonadism-related disease (e.g. Klinefelter syndrome), or based solely on a defined biochemical cut-off (e.g. serum testosterone <10 nmol/L), giving rise to conflicting narratives. Cross-sectional and longitudinal epidemiologic data have identified an age-related decline in serum testosterone, particularly the circulating free fraction, and yet much of this results from accumulating co-morbidities, such as obesity, chronic disease, medications and frailty, rather than from primary disorders of the hypothalamo-pituitary-gonadal axis, or even from ageing *per se*<sup>1,2</sup>. Nevertheless, although hypogonadism-associated conditions may be individually rare, the large number and diversity of these conditions results in a cumulatively significant mass of patients. This is likely to increase with more cancer survivors, gonadectomised female-to-male gender transitions, primary care opiate scripts, and



greater numbers of diagnosed Klinefelter cases. In the UK healthcare environment, these men largely depend on Endocrinologists for an accurate diagnosis and long-term management plans. The Society for Endocrinology (SfE) is a professional and scientific body dedicated to the advancement of knowledge and promotion of good practice in the field. Although based in the United Kingdom, it is not a narrowly national body and, indeed, a significant number of committee members and officers practice in the Republic of Ireland. The SfE's Clinical Committee commissioned this Guideline and appointed CNJ and RQ as co-chairs. The Clinical Committee and co-chairs nominated a working-group to represent multiple disciplines relevant to the guideline. A patient member was also nominated to attend all meetings, and approve decisions with other working group members. Meetings (face-to-face and remote) were held between 2019 and 2020 to assign specific areas of the guideline scope to members of the working group to perform narrative reviews of the literature and provide reports on their topic. Individual reports were peer-reviewed by other members of the working group. Where consensus could not be reached on specific points, the co-chairs made decisions on content. An advanced draft of this guideline was revised following peer review by the SfE Clinical Committee, prior to submission for publication.

## **2. Aetiology of male hypogonadism**

Making a clear distinction between Primary Hypogonadism (PH) and Central Hypogonadism (CH) through measurement of serum LH and FSH levels, as opposed to making a non-specific diagnosis of "testosterone deficiency" or "low testosterone", is a mandatory clinical requirement under all circumstances, because the outcome of this analysis determines:

1. The available first-line options for inducing/restoring fertility, which differ fundamentally: gonadotrophin therapy to induce spermatogenesis in CH *versus* mTESE, donor sperm or adoption, as potential options to becoming a parent.

2. The palette of potential differential diagnoses, which can in turn signpost specific disease management strategies beyond testosterone therapy, *e.g.* mitigation of the risks of developing type 2 diabetes (T2DM), cancer, or venous thromboembolism in men with Klinefelter syndrome; screening for the presence of hyperprolactinaemia, iron overload, wider pituitary dysfunction, or parasellar mass lesion in CH.
3. The nature of any confirmatory or second line investigations required, such as pituitary biochemical profiling and imaging in CH, *versus* karyotype/copy number variation in PH.
4. Confirmation of the diagnosis of MH through further contextual clinical ascertainment. For instance, the diagnosis is invariably secure when basal biochemistry indicates PH, but further contextual clinical ascertainment is required to properly distinguish CH (for which testosterone treatment is first line therapy) from NGI, for which first-line interventions are instead directed at lifestyle-coaching, disease-management, or addressing general health needs.

It is crucial to identifying the aetiology of CH is ruling out potential causes and confounders, which demands contextual clinical history, physical examination, medication review and biochemical assessment under controlled conditions, usually on more than one occasion.

### *2.1. Primary Hypogonadism*

Primary Hypogonadism (PH) is characterized by elevated serum gonadotrophin levels in the setting of low testosterone levels due to Leydig cell dysfunction (whether impaired cellular function, or reduced cell mass). It may be accompanied by impaired or absent spermatogenesis. Some testicular disorders underlying hypogonadism are exceedingly rare, such as congenital anorchia (*i.e.* vanishing testes), Leydig cell hypoplasia secondary to inactivating mutations of the LH receptor <sup>3</sup>, *dystrophia myotonica* and Kennedy syndrome, but much more common are cryptorchidism, trauma, orchitis, Klinefelter syndrome, post radiotherapy or chemotherapy

184 damage, and male ageing. An under-reported feature of PH is a 3-fold greater prevalence of  
185 MetS and T2DM, albeit the direction of causation is unclear <sup>4-6</sup>.

## 187 2.2. *Cryptorchidism*

188 The lower temperature of the scrotum (compared to the abdomen) is critical for Sertoli and  
189 germ cell function and survival. Approximately 1-2% of males are born with cryptorchidism  
190 that persists beyond 3-4 months postnatal and 80-90% of cases are unilateral <sup>7</sup>. Testes that  
191 remain in the inguinal canal (or abdomen) beyond the first year of life have significantly  
192 reduced function and it is recommended that surgical correction of undescended testes is  
193 performed in the first year of life, usually after six months when anaesthetic risks diminish <sup>8</sup>.  
194 Even in unilateral cryptorchidism, the contralateral testis is not completely normal suggesting  
195 that cryptorchidism is a bilateral disease <sup>9</sup>. There are concerns that endocrine disruptors  
196 (chemicals in the environment – air, soil, or water supply – food sources, personal care  
197 products and manufactured products that interfere with the normal function of the endocrine  
198 system) may be contributing to a rising incidence <sup>10</sup>.

## 200 2.3. *Klinefelter syndrome*

201 Klinefelter syndrome (KS) with a 47XXY or 48XXXY karyotype is the most common  
202 chromosomal aneuploidy and the most common form of PH in males, occurring in  
203 approximately 1:660 males <sup>11</sup>. The gonadal phenotype comprises seminiferous tubule atrophy,  
204 disrupted spermatogenesis and small testes, but with Leydig cell function preserved in the  
205 initial life stages. Gynaecomastia is prominent, along with behavioural and neurocognitive  
206 problems, and tall stature resulting from 3 copies of the SHOX gene. Only 10% of patients  
207 with KS are diagnosed before puberty and approximately 25% are never diagnosed <sup>11</sup>. This

likely reflects a combination of poor medical training in reproductive medicine and mosaic forms of KS having a milder clinical phenotype with non-specific symptomatology.

Serum LH, FSH and inhibin B (InB) levels are typically normal until puberty, at which point seminiferous tubules degenerate, losing germ cell, then Sertoli cells and eventually hyalinise and testicular function progressively declines, with testicular volume rarely exceeding 5-6 mL

<sup>11</sup>. Testosterone therapy becomes mandatory when serum T concentrations become hypogonadal, or when clinical features develop. However, there is a view that testosterone treatment should also be considered from the point at which serum gonadotrophins begin to rise in early puberty, so as to ensure full development of secondary sexual characteristics and optimise bone health <sup>11</sup>.

Reports have identified increased risk for mediastinal tumours, autoimmune disorders, vascular disease, thromboembolism and cancer in cohorts of patients with KS, some of which may relate to poorer lifestyle. As with other forms of PH, there is an approximately tripled risk for metabolic complications including obesity, MetS and T2DM. Accordingly, lifestyle coaching should be part of regular consultations along with ongoing monitoring of bone health with densitometry and regular assessment of adherence to testosterone therapy. In addition to these health problems and the physical stigmata of KS, affected boys often have poor motor skills, behavioural problems and may exhibit neurocognitive deficits <sup>12</sup>. While highly variable, many patients with KS have problems with cognition and language acquisition such as dyslexia, learning disabilities and difficulties with executive function. These difficulties often require speech and language therapy, special education programmes and/or psychological counselling.

The combination of cognitive behavioural problems and hypogonadism can negatively affect quality of life and prevent effective adaptation to living with KS <sup>13</sup>. Impulsivity and anger-management issues may be inherent to the condition but are unlikely to be caused or exacerbated by physiological testosterone therapy. A multi-disciplinary approach including

medical, nursing, psychological and social care can assure assessment of psychosocial concerns, discussing these aspects with patients and families, identifying educational or employment and social resources, and making appropriate inter-professional referrals as needed. With increasing age, the diagnostic yield from screening for KS among men presenting with PH progressively falls and its clinical utility becomes less apparent.

#### *2.4. Acquired primary hypogonadism*

Acquired PH in men may result from trauma, infection, or inflammation (*i.e.* mumps orchitis), medical / surgical interventions, systemic disease, or chronological ageing (**Table 1**), albeit an underlying cause frequently cannot be identified. Unlike in women, there does not appear to be a syndrome of primary, autoimmune testicular insufficiency. Orchitis may occur secondary to viral infection and develops in around 25% of mumps infections among post-pubertal men<sup>14</sup>. Unilateral inflammation occurs in approximately two-thirds of patients and can lead to loss of testicular volume, but fertility is maintained in 75% of cases. Bilateral orchitis is less common, but spermatogenesis recovers in only a third of men<sup>14</sup> and an unknown proportion develop PH. The European Male Ageing Study (EMAS) found that 1–2% of older men had PH and another 10% had compensated primary hypogonadism (CPH), which were associated in equal measure with burden of comorbidities and chronological age<sup>15</sup>; the SPECT-China study showed similar findings were very similar<sup>6</sup>. Unlike the menopause in females, the majority of older men in the general population maintain adequate gonadal function, while the small minority of men who develop hypogonadism usually have poor health with multiple comorbidities and/or obesity.

**Insert Table 1 here**

#### *2.5. Hypothalamic and pituitary disorders – Central hypogonadism (CH)*

Testosterone secretion is contingent upon adequate LH stimulation of the Leydig cells. Hypogonadism resulting from inadequate gonadotrophin stimulation is biochemically evident in low (or inappropriately normal) serum gonadotrophin levels. CH can be congenital or acquired (**Table 1**) and results from either defects at the level of the hypothalamus (*i.e.* isolated GnRH deficiency), pituitary defects causing inadequate gonadotrophin release, genetic mutations resulting in inadequate action of GnRH or gonadotrophins, or functional suppression of the hypothalamo-pituitary-gonadal (HPG) axis<sup>16</sup>. However, certain conditions can lead to a false-positive biochemical “diagnosis” of CH, which include venepuncture performed in the non-fasted state, in the afternoon, during intercurrent illness, sleep-deprivation or from taking undeclared medicinal or recreational drugs. This emphasises the importance of a comprehensive history that accounts for contextual clinical correlation factors and venepuncture under standardised conditions (8-10 am, fasted and well-rested).

#### *2.6. Congenital hypogonadotrophic hypogonadism*

Congenital hypogonadotrophic hypogonadism (CHH) is a rare disorder (1/4,000–10,000 males) caused by isolated GnRH deficiency and clinically characterized by absent or incomplete puberty and infertility<sup>16</sup>. When CHH occurs with anosmia (lack of sense of smell), it is termed Kallmann syndrome. While sense of smell and reproduction may appear to be unrelated functions, the embryonic origins of GnRH neurons in the olfactory placode provide the development link. More than 30 genes have been identified as underlying CHH and Kallmann syndrome either alone or in combination<sup>16-18</sup>. Some gene mutations disrupt GnRH neuron development and migration manifesting as Kallmann syndrome; others may disrupt GnRH homeostasis and secretion and clinically present as cases of normosmic CHH<sup>16</sup>. In some cases, mutations in the gene encoding the GnRH receptor (*GNRHR*) result in decreased GnRH action and CHH ensues (described below). CHH may occur with other associated phenotypes

such as cryptorchidism with or without micropenis, renal agenesis, hearing loss, midline defects (cleft lip/palate) and skeletal anomalies. CHH can be difficult to distinguish from other causes of pubertal delay and, consequently, many patients are diagnosed late with significant psychosocial impact<sup>19</sup>. These patients need of psychological support and may benefit from peer-to-peer support. Effective treatments are available for inducing secondary sexual characteristics and fertility in most men with CHH<sup>16,20</sup>. Spontaneous fertility has been reported; on rare occasions associated with “fertile eunuch” or Pasqualini syndrome, but more commonly with the hormonal reversal of CHH that is observed in about 10-15% of cases following treatment, but may not be sustained and thus warrants ongoing monitoring<sup>21</sup>.

#### *2.7. Other syndromic forms of congenital central hypogonadism*

Developmental defects can result in hypothalamic-pituitary dysfunction CH. Many problems present with a constellation of features and thus are referred to as syndromic forms. These cases are typically identified during childhood, as anterior hormone deficiency, adrenal failure, obesity, or neurologic aspects command attention well before absent puberty manifests<sup>22</sup>. Given the complexity of these cases patients and families need purposeful planned transitional care to ensure continuity and ongoing support.

#### *2.8. Combined pituitary hormone deficiency (CPHD) and septo-optic dysplasia (SOD)*

Patients with combined pituitary hormone deficiency (CPHD) are often diagnosed early in childhood and treated for the respective pituitary hormone deficiencies, yet gonadotrophin deficiency may not become apparent until the failure of puberty to commence spontaneously. Importantly, these patients are responsive to treatment inducing secondary sexual characteristics and fertility<sup>23</sup>. A number of genes have been identified to underlie this condition yet the majority of cases remain without an identified genetic cause<sup>24</sup>. Septo-optic

dysplasia (SOD) is a developmental brain malformation that can present with pituitary hormone deficiencies, severe visual impairment, neurocognitive disability and developmental disorders on the autism spectrum<sup>25</sup>. Notably, genetic overlap has been reported between SOD, CPHD, CHH and CHARGE syndrome<sup>18,26</sup>.

## 2.9. CHARGE, Bardet-Biedl and Prader Willi Syndromes

The constellation of coloboma (ocular malformation of the lens, iris, or retina), congenital hear defects, choanal atresia (abnormal formation of the nasal cavity), retardation of growth and development, genital hypoplasia, and ear anomalies associated with deafness define CHARGE syndrome<sup>27</sup>. In addition to immunologic problems, patients with CHARGE syndrome may exhibit hypogonadotrophic hypogonadism necessitating treatment. Approximately two-thirds of cases are explained by mutation Chromodomain-helicase-DNA-binding protein 7 (*CHD7*)<sup>27</sup> a gene also involved in CHH and Kallmann syndrome<sup>16</sup>. Bardet-Biedl syndrome (BBS) is a recessive genetic disorder of the cellular cilia that may present with a wide range of clinical features (obesity, mental retardation, renal anomalies, polydactyly, retinal degeneration, as well as cardiovascular, hepatic and metabolic problems<sup>28</sup>. In addition to being clinically heterogeneous, BBS is genetically diverse with 19 identified loci and complex genetics (i.e. digenicity, oligogenicity)<sup>28</sup> akin to CHH and Kallmann syndrome<sup>16</sup>. Although traditionally associated with CH, a recent clinical study found no evidence for hypogonadism among males with BBS when this was screened for systematically<sup>29</sup>. Prader Willi syndrome (PWS) is a rare genetic disorder (1/10'000-25'000) on chromosome 15 that causes physical, mental and social disability. During infancy, PWS is characterized by hypotonia and poor feeding (failure to thrive). Subsequently, additional features such as developmental delays, cognitive disability, short stature, hyperphagia, obesity, and behavioural problems (i.e. obsessive food seeking)



emerge<sup>30</sup>. Multiple endocrine deficiencies are common with patients typically needing growth hormone and testosterone therapy<sup>31</sup>.

#### *2.10. Adrenal hypoplasia congenita*

A rare form of hypogonadotrophic hypogonadism occurs in the setting of adrenal hypoplasia congenital. Mutations in Nuclear receptor subfamily 0, group B, member 1 (*NR0B1*, formerly *DAX1*) result in early adrenal failure, and subsequently absent/incomplete puberty is the initial sign of CH<sup>32</sup>.

#### *2.11. Acquired central hypogonadism (CH)*

In this situation, CH develops in adult life following prior full pubertal development and can result from trauma (*e.g.* skull fracture, pituitary stalk dissection and, particularly, military blast trauma), vascular events (*e.g.* pituitary apoplexy), infiltrative or metabolic disorders (*e.g.* iron overload, or hypophysitis), parasellar tumours, surgery, radiotherapy, hyperprolactinaemia, energy-deficit, or illicit drug use (*i.e.* marijuana, opiates or androgens)<sup>14</sup>.

*Anabolic androgens:* Anabolic androgens are testosterone-like substances exerting powerful effects on the muscle, bone, reproductive health, cardiovascular system, brain, and behaviour<sup>33</sup>. Most men taking anabolic androgens, do so for cosmetic rather reasons rather than for athletic performance. The supra-physiological androgen levels suppress the HPG axis, resulting in testicular atrophy and infertility which can be reversible. In addition, affected men may develop psychiatric disturbances including mania, depression and anxiety, together with psychical and psychological dependency. However, as androgens are typically abused in very high doses and as some products have an extended half-life, recovery of HPG axis function can take from several months to a year or longer<sup>33-34</sup>, with fertility taking up to 3 years to fully recover<sup>34</sup>. Significantly, levels of Insulin-like Factor 3 (INSL3) remain low for at least 3 years

following cessation of androgen abuse, independently of testosterone, suggesting a persistent impairment of Leydig cell function <sup>35</sup>.

In adult-onset isolated GnRH deficiency, men who previously completed puberty present in adulthood with CH secondary to profound HPG axis suppression and complete loss of LH pulsatility <sup>36</sup>. These men have no other apparent underlying cause of their hypogonadism and defect is identified as hypothalamic as they respond to physiologic pulsatile GnRH therapy. Long-term follow up studies suggest that the neuroendocrine defect is permanent as these men do not subsequently regain HPG axis function <sup>37</sup>.

#### *2.12. Parasellar tumours causing central hypogonadism*

Craniopharyngiomas, Rathke's cleft cysts, pituitary adenomas, gliomas, germinomas, and meningiomas can cause CH. As space-occupying lesions, compression and destruction of the hypothalamic-pituitary region can impair GnRH-induced gonadotrophin secretion. In adults, prolactin-secreting pituitary adenomas (prolactinomas) are the most frequently encountered and can cause functional HPG axis suppression in addition to CH from mass-effect <sup>14</sup>.

#### *2.13. Iatrogenic central hypogonadism*

Common causes include surgery, chemotherapy, radiation treatment, long-term high-dose glucocorticoid treatment, or opiates used for chronic pain management or narcotic addiction <sup>38</sup>, along with androgen deprivation therapy (ADT) for prostate cancer, for which the achievement of CH is the goal of treatment. Finally, transgender males also require testosterone therapy, which is generally sufficient to suppress hypothalamo-pituitary-ovarian function pending oophorectomy, but in the interim may be combined with a GnRH analogue or progestogen (systemic or intrauterine) should amenorrhoea not be achieved by testosterone alone.

#### 2.14. Functional central hypogonadism

CH can also result from physiological causes and this is better known in females, where physical, emotional, or nutritional stressors can result in suppression of menses (functional hypothalamic amenorrhea)<sup>39</sup>, albeit there may also be a genetic propensity<sup>40,41</sup>. However, males appear more resistant to hypothalamic suppression from either excessive exercise or energy deficits, as only small series have been reported to date and, moreover, genetic influences have not been identified<sup>42</sup>. Typically, such cases are restricted to patients with eating disorders (*i.e.* anorexia nervosa) or endurance athletes on very low-fat diets. A much more common form of functional hypogonadism results from hyperprolactinaemia suppressing hypothalamic GnRH secretion. Elevated serum prolactin levels may result from physiologic causes (*e.g.* stress, illness, sleep deprivation), pathophysiologic (*i.e.* prolactinoma) or iatrogenic causes (*i.e.* dopamine antagonist drugs)<sup>43</sup>. Notably, dopamine negatively regulates prolactin secretion while serotonin has a stimulatory role. Thus, both dopamine-antagonist antipsychotic drugs and serotonergic anti-depressants can cause elevated prolactin levels and may induce hypogonadism<sup>43</sup>. Opiates (see 2.13) are another common cause of functional central hypogonadism. Importantly, the HPG axis recovers once the underlying stimulus to energy-deficit or hyperprolactinaemia (or the opiate drug itself) is removed, and the evidence for benefit of testosterone treatment is patchy, particularly in respect of opiates, wherein many adverse impacts on health arise independently of hypogonadism. Nevertheless, as the clinical features of these forms of functional hypogonadism (sexual dysfunction, fatigue, anaemia, osteoporosis, sarcopaenia, gynaecomastia and infertility) are so strikingly congruent with those of permanent forms of MH, testosterone treatment should generally be prescribed unless resolution or removal of the stimulus to MH is anticipated within a reasonable timeframe.

#### 2.15. Systemic disease – non-gonadal illness (NGI)

Stress from acute illness, including surgery, burn injuries, myocardial infarction, stroke and sepsis have all been noted to suppress the HPG axis<sup>44</sup> and, when stress becomes prolonged as per any chronic illness, suppression of GnRH-induced gonadotrophin secretion becomes entrenched<sup>45</sup>. NGI is also observed in relation to ageing and obesity (see below). Importantly, this effect is reversible upon recovery from or remission of the underlying disease process. The evidence basis for testosterone treatment of NGI arising from these conditions is slim.

#### *2.16. Ageing and central hypogonadism*

Four key epidemiologic studies, as summarised by Dean et al, examined testosterone deficiency in ageing Western men: 1) the Massachusetts Men's Aging Study (n >1,600, aged 40-70 years), 2) Boston Area Community Health Survey (n >1,400, aged 30-79 years), 3) Hypogonadism in men (n >2,100, aged >45 years), and 4) the European Male Ageing Study (EMAS) (n>3,000, aged 40-79 years)<sup>46</sup>. These studies point to a progressive decline in serum T with age and alterations in sex hormone binding globulin (SHBG). The Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China study) found a similar fall in testosterone levels to EMAS up to and including middle age, whereas older men who had maintained traditional non-Western diet and largely avoided weight-gain did not exhibit lower testosterone levels than younger Chinese men<sup>6</sup>. Historically, several terms were used to describe the age-related fall in serum testosterone, including male menopause, andropause, and androgen deficiency syndrome of the aging male. The EMAS multicentre European cohort study provided much-needed clarity and defined "late-onset hypogonadism" (LOH) as at least three sexual symptoms (decreased sexual interest, morning erections and erectile dysfunction [ED]) in the setting of a total serum testosterone level <11 nmol/L and calculated free testosterone <220 pmol/L<sup>47</sup>. Importantly, low serum T levels combined with potentially attributable sexual symptoms only occur in a small minority of ageing men (2-6%) and can be

largely attributed to comorbidities causing gonadotrophin suppression (*i.e.* NGI), and in particular obesity. Therefore the priority is to address or treat comorbidities as far as possible, with the evidence for benefit of testosterone treatment being slim. In contrast, as outlined in section 2.4, both EMAS and SPECT-China crucially identified a small subset of older men (1-2%) having acquired *primary* hypogonadism that was equally associated with chronologic age and comorbidities <sup>46</sup>.

#### 2.17. Obesity and male hypogonadism

There are consistent data showing a negative correlation between obesity and testosterone, irrespective of age <sup>15,48</sup>. Obese men often exhibit low-normal serum gonadotropins with slightly low testosterone, but this is reversible and studies of lifestyle modification (*i.e.* diet and exercise) or bariatric surgery show that the rise in serum testosterone is proportional to the amount of weight lost <sup>48,49</sup>. The relationship between testosterone and fat (obesity) appears to be bi-directional, with several underlying mechanisms underpinning this. Lower serum testosterone levels result in decreased lean muscle mass and increased fat mass, which in turn promotes adipocyte-aromatase-mediated conversion of testosterone to oestradiol, thereby directly decreasing circulating testosterone, as well as doing so indirectly via oestradiol-mediated suppression of GnRH secretion, creating thus a vicious cycle. Other contributing factors include the dysregulated signalling of leptin, adiponectin and gut hormones (ghrelin, peptide YY), the effects of pro-inflammatory adipocytokines (*e.g.* tumour necrosis factor alpha, interleukin <sup>50</sup> and physiologic stressors accompanying obesity (*e.g.* chronic diseases such as metabolic syndrome, sleep apnoea and arthritis), overall constituting non-gonadal illness (NGI) <sup>48</sup>. However, due to the inhibitory effect of hyperinsulinaemia on hepatic SHBG secretion, obese men tend to run low SHBG levels, such that measurement of total testosterone may at first sight appear to indicate a CH (or NGI) biochemical picture, whereas in fact free T is likely

to be normal. These men are not usually anaemic, osteopaenic, or infertile and thus the mainstays of management are lifestyle change, weight loss and the identification and treatment of other obesity-associated comorbidities, such as sleep apnoea. Although testosterone treatment may improve lean body mass and surrogate markers of cardio-metabolic metabolic health in these men, the erythrocytosis that is frequently induced thereby makes the overall balance of benefits versus risks far less clear.

### **3. Diagnosing male hypogonadism**

The diagnosis of MH requires a combination of characteristic clinical features and corroborative biochemistry. Lacking any relevant clinical features or risk factors on medical history, there would usually be no justification for initiating a biochemical workup. The diagnosis of MH may be obvious due to strong risk factors including pubertal delay<sup>51</sup> prior cancer alkylating therapy, radiotherapy or orchidectomy, and known Klinefelter syndrome. However, the diagnosis of MH may be challenging because some clinical features may be non-specific. Clinical features suggestive of MH comprise the sexual (reduced libido and sexual activity, erectile dysfunction and reduced spontaneous erections), skeletal (loss of height, low trauma fractures and low bone density), reproductive (cryptorchidism, infertility or low sperm count), vasomotor (hot flushes and sweats), haematological (reduced haemoglobin or haematocrit in the absence of other identifiable cause) and tender glandular gynaecomastia. By contrast, symptoms such as disturbances of mood, sleep, or neurocognitive function, reduced muscle mass and strength and increased body fat appear to be less specific to MH<sup>1</sup> and, indeed, are much less likely to improve with testosterone treatment<sup>52</sup>. A targeted medical history is required identify confounding factors that might affect the interpretation of the biochemical profile, such as non-gonadal illness, energy deficit or excess, and drugs particularly androgens,

opiods, glucocorticoids and cannabinoids. Examination should note if voice tone is pre- or post-pubertal, male pattern hair development, gynaecomastia, testicular volume, and evidence of cryptorchidism or orchidopexy.

A variety of criteria have been proposed for the diagnosis of MH as discussed in two recent reviews comparing current guidelines <sup>53,54</sup>. A harmonised reference range for serum total testosterone has been calculated in over 9,000 healthy non-obese young men from Europe and North America using the Centers for Disease Control and Prevention (CDC) reference method; the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile were reported as 9.2nmol/L and 31.8nmol/L, respectively <sup>55,56</sup>. However, the diagnosis of MH also needs to take into account the presence of clinical features likely caused by low testosterone. The EMAS study observed that in approximately 3,400 men aged 40-79 years, the odds of experiencing sexual symptoms increased with either a total testosterone <8nmol/L (regardless of calculated free testosterone) or total testosterone <11nmol/L (with cFT<220pmol/L) <sup>47</sup>; men with levels of testosterone above these threshold were no more likely to experience symptoms related to hypogonadism than the background population. The presence of specific risk factors described above and diagnostic features such as anaemia and low bone mineral density can help make the diagnosis where results are equivocal.

It is also important to consider the potential clinical benefits of testosterone treatment for men with MH. Results from a systematic review and meta-analysis demonstrated that testosterone treatment improves sexual symptoms in men with serum testosterone <8 nmol/L unrelated to non-gonadal illness <sup>57</sup>. However, there is a paucity of published evidence investigating the clinical effects of testosterone treatment in men whose baseline serum total testosterone is >12nmol/L. Although the clinical effects of testosterone treatment in men *without* hypogonadism represent an interesting area of research, there is currently insufficient evidence to be able to translate this into clinical practice and testosterone treatment is not licenced in

men without MH<sup>58</sup>. In summary, a multi-method approach is necessary to establish the diagnosis of MH, though it is evident that the higher the serum testosterone threshold is set, the greater the risk of making an incorrect diagnosis of MH. This emphasises the importance of contextualising clinical and laboratory information when making a differential diagnosis.

#### **4. Analytical performance of serum testosterone assays for men**

The UK National External Quality Assurance Scheme (NEQAS) for Steroid Hormones monitors laboratory performance in the measurement of serum testosterone, SHBG and the derived analyte Free Testosterone. Most laboratories use either commercial diagnostic kits using an immunoassay principle or a Mass Spectrometry method. Overall, the performance of these tests is generally acceptable compared to other hormone analytes. The UK NEQAS for Steroid Hormones has trend data covering many years allowing to gauge the current state-of-the-art. Method bias, when compared to the reference value, does shift over time within any laboratory and an assay which is unbiased today could nevertheless drift into having a 5% bias over a period of years. Although mass spectrometry (MS) performance for testosterone levels in the female range is superior to that of immunoassays (many of which display a concentration-dependent bias with a negative bias at lower concentrations), the performance of some immunoassays outperforms MS methods in the male range. The between-laboratory agreement for some immunoassays can be as good as 4% CV, whereas MS users vary by up to  $\pm 10\%$ , which could be considered a desirable performance limit. Therefore, MS is by no means the gold standard that was previously supposed and, at present,  $\pm 15\%$  is used as the definition of out-of-consensus performance. The recovery of added testosterone for most methods is not quantitative and can be as high as 130% and as low as 90% for some of the major methods<sup>59</sup>.

##### **4.1. Free testosterone**



532 Testosterone circulates bound to plasma proteins, predominantly albumin and, particularly, sex  
533 hormone binding globulin (SHBG). However, levels of testosterone and its binding proteins  
534 can vary considerably between and within individuals due to physiological and pathological  
535 causes. Concentrations of SHBG can vary depending on variables such as diet, body mass  
536 index (BMI), insulin, thyroid and sex steroid hormone concentrations, and age <sup>60-69</sup>. In these  
537 situations, measurement or calculation of free testosterone should provide added confidence in  
538 the differentiation between mild hypogonadism and eugonadism <sup>70,71</sup>.

539 There are four approaches to estimating free testosterone, comprising direct measurements of  
540 free testosterone by 1. equilibrium dialysis, 2. ultra-centrifugation, or 3. gel filtration, and 4.  
541 calculation of the free testosterone fraction by mass action formula based on the binding  
542 characteristics of SHBG and albumin. It is generally accepted that all three methods of direct  
543 measurement are technically demanding, are not available to routine clinical laboratories and,  
544 crucially, lack much in the way of clinical correlation to established measures of androgen  
545 action, such as sexual function, bone mineral density and haemopoiesis. The commonly used  
546 alternative is to calculate the free fraction, for which there are several available formulae,  
547 though they all give different results possibly due to SHBG and albumin having inconstant  
548 binding characteristics (Heinrich-Balard et al 2015; Goldman et 2017). CFT using the  
549 Vermeulen formula has been increasingly used in clinical practice over the past 20 years and  
550 the calculated free testosterone results have shown clinical validity in many studies <sup>62,72-81</sup>. The  
551 original Vermeulen equation was validated using assays for testosterone and SHBG that are no  
552 longer available but has recently been re-validated using current state-of-the-art methods <sup>61</sup>.

553 Calculated free testosterone has been increasingly used in clinical practice over the past 20  
554 years. However, the implementation is challenged by the variability of analytical methods for  
555 testosterone and SHBG used in routine clinical laboratories. These variations as well as the  
556 various equations to calculate free testosterone have a significant impact on the results reported

by clinical laboratories. The most recent data from UKNEQAS show that there are seven methods for testosterone and six methods for SHBG in common use<sup>59</sup> which creates a myriad of combinations and calculated free testosterone results<sup>60,61,63,66-68</sup>. It is essential, therefore, that each combination of assays has its own specific reference ranges and decision limits for free testosterone, and this requires close collaboration between clinical and laboratory specialists. Clinicians and laboratories should avoid using generic or extraneous reference ranges, in order to safeguard against misclassification of patients<sup>1,82</sup>. It is important to highlight that the accuracy and clinical utility of free testosterone quantification is limited in the absence of these precautions; future efforts to resolve these issues would reduce risks of misdiagnosing men with symptoms suggestive of hypogonadism.

In summary, total testosterone is the unchallenged first-line investigation for suspected hypogonadism. Calculated free testosterone is used only as a second-line test in conditions associated with deranged SHBG concentrations, or when total testosterone is in the borderline range for patients with clinical features suggestive of androgen deficiency. However, the use of free testosterone is still controversial<sup>64</sup> and it is impossible to derive accurate free testosterone estimations without tightly regulated testosterone and SHBG assay performance.

## **5. Testosterone therapy**

MH is associated with several physical, psychological, and social symptoms and, with rare exceptions, patients require long-term testosterone treatment and older age or disability should be no barrier for initiating testosterone treatment. Current treatment formulations and modalities for testosterone treatment, though not yet perfected, can offer an individualized treatment regime if accompanied by appropriate patient education and shared decision making. Given the complexity of testosterone treatment, it is crucial that patients understand and engage

with their treatment planning, and are supported to self-monitor testosterone treatment in order to recognise and manage potential adverse effects<sup>83</sup>.

Currently available testosterone formulations, dosage, administration and benefits and disadvantages of each formulation are presented in **Table 2**<sup>1,83,84</sup>. The clinician should support the patient to identify a suitable testosterone formulation through a structured needs assessment and by providing patients with a rationale of benefits and disadvantages of each testosterone treatment formulation<sup>83</sup>. The most used formulations in the UK are transdermal gels and intramuscular injections.

**Insert Table 2 here**

### *5.1. Testosterone transdermal gel*

This is a clear alcohol gel applied once a day, preferably in the morning, to dry, clean, unbroken and healthy skin, excluding the genital area. The gel is absorbed rapidly through the skin within 5–10 min and testosterone level elevate to the reference range within 2–4 h after application. Dose titration, aiming for mid-normal reference range for total testosterone, is based on blood test taken approximately 2–6 hours post-gel application, avoiding the gel application site<sup>85,86</sup>. Full absorption of the gel may take up to six hours and, therefore, showering or swimming within that time should be avoided. It is important to advise patients on the potential risk of direct skin-to-skin transfer of testosterone. Transfer of testosterone gel to pregnant women may cause abnormalities or harm to the unborn baby. To minimise risk of transfer, patients are advised to: wash hands thoroughly immediately after applying the gel; cover the application site (shoulders, upper arms, abdomen) with clothing once the gel has dried; shower before any situation involving close skin-to-skin contact within 6 hours after applying the gel.

Testosterone gel is well tolerated; however, occasional irritation or dryness may occur which patients can treat with unscented moisturising topical creams.

## *5.2. Testosterone intramuscular injections*

These injections are administered intramuscularly (IM) into the gluteal muscle or upper thigh, although improved pharmacokinetics and potentially greater tolerability have been reported with off label subcutaneously (SC) injection<sup>87</sup>. They are oily preparations (such as castor oil) which allow slow release over a long period after being injected. Most patients have their injection given by their GP or practice nurse, which often causes restrictions in lifestyle. Testosterone injections provide high levels of testosterone (peaks) shortly after the injection, which tend to drop below the reference range (troughs) towards the end of the injection interval. This results in some patients experiencing symptoms related to high and low testosterone levels between the injections, such as mood swings, difference in energy levels and sexual drive which can be more prominent with the short acting IM injections.

Testosterone injections (**Table 2**) may be either of the following:

1. *Short acting* administered IM every 2-4 weeks or SC once a week depending on formulation and patient response. Administration of testosterone cypionate and enanthate by SC injection at 50-100 mg once a week has comparable pharmacokinetics, safety and tolerability to IM administration and a steady state concentration of serum testosterone between dose intervals<sup>87,88</sup>. This can also support patient self-management as self-administration is more feasible than IM injections. Education is important to consult patients and their families on how to monitor improvement in well-being and response to treatment and any potential side effects as well as peak and trough levels between injections<sup>83</sup>.

2. *Long-acting* testosterone undecanoate 1 g/4 mL IM injections, typically every 10–14 weeks although much longer intervals may be needed. This should be warmed and injected very

slowly deep into the gluteal muscle, to minimise injection-related pain and risk of micro-embolism. The first and second injections are given 6–8 weeks apart as a loading dose, with the third injection given 12 weeks later. However, for the graded induction of puberty in men and older teenagers, the 6–8 week loading dose should be omitted<sup>89,90</sup>. A testosterone level and full blood count measured just prior to the third injection will then determine the frequency of future injection intervals. Other things being equal, the interval between injections is set to achieve a trough testosterone at the lower end of the normal reference range<sup>91,92</sup>, but other factors such as adverse effects, haematocrit, bone density and clinical well-being also need to be factored-in<sup>54</sup>. Once steady-state has been achieved, trough bloods should be measured every 3–5 injections or annually, depending on the final injection interval; it is not usually necessary to draw blood with each injection.

### *5.3. Benefits of testosterone treatment and side effects*

The objective of testosterone treatment is to reverse or prevent the symptoms and long-term effects of MH and to maintain general well-being<sup>1</sup>. Optimised testosterone treatment can:

- Induce or complete secondary sexual development
- Improve sex drive, libido and sexual function
- Improve mood and well-being
- Improve muscle mass and strength
- Restore or maintain masculine characteristics such as facial and body hair
- Maintain bone strength and prevent osteoporosis
- Maintain red cell production and prevent anaemia.

testosterone treatment suppresses gonadotrophin secretion and is therefore unsuitable for men during conception (see section on “fertility considerations”). It is important to consult the patient on what to expect from testosterone treatment and the estimated time periods when he

will experience the benefits of testosterone treatment. Setting realistic expectations and supporting the patient to recognise and manage potential testosterone treatment side effects effectively has a significant impact on treatment adherence<sup>83</sup>. Effects of testosterone treatment on sexual and quality of life parameters can appear within 3-6 weeks, such as improvement in sexual interest, depressive symptoms and energy levels, but changes in physical parameters, such as erythropoiesis, lipids, fat mass, lean body mass, glycaemic control, muscle strength and bone density may require 6-12 months to become apparent<sup>93</sup>.

The suitability of each treatment option and any formulations-specific side effect as outlined in **Table 2** should be assessed and addressed at each consultation. Potential side effects described with testosterone treatment include acne, headache, irritability, aggressiveness, mood swings, depression, weight gain, oedema, prolonged painful or frequent erections, gynaecomastia, increased haematocrit and male pattern baldness<sup>1</sup>. However, these side effects can be significantly minimised with optimised testosterone treatment; noting also that symptoms such as mood swings, depression, gynaecomastia and irritability are also prominent in undertreated hypogonadism. The patient should be advised to monitor and discuss any of these side effects with their endocrine team to review and adjust their treatment regime. A symptoms diary is often very helpful which can be cross-checked against the biochemistry results and testosterone treatment formulation.

## **6. Post-finasteride syndrome and anabolic androgens**

Finasteride is a 5 $\alpha$ -reductase enzyme inhibitor used in the treatment of benign prostatic hypertrophy and male androgenetic alopecia (AGA). Patient self-reported studies show that finasteride causes adverse drug-related reactions with sexual impairment (decreased libido, erectile dysfunction, ejaculation problems), depression, anxiety, and physical symptoms that persist after treatment discontinuation and can be permanent for some patients, though their

long-term impact and precise mechanism have not been clarified<sup>94,95</sup>. A recent study of 55 men treated with finasteride for AGA found no significant difference in all sperm parameters, serum, FSH, LH, testosterone, prolactin and oestradiol level at treatment initiation (T0), a year after treatment (T12) and a year post-treatment discontinuation (T24)<sup>96</sup>. Current evidence does not support indication of testosterone treatment in the treatment of post-finasteride syndrome<sup>97,98</sup>. Men on finasteride should be counselled about the possibility of these adverse effects and warned that unwanted symptoms can persist after treatment discontinuation, the origin of which remains unclear. Patients should be referred to psychology services for relevant therapeutic interventions<sup>99</sup>.

Some retrospective series have explored the potential of hormone therapy including hCG and selective oestrogen receptor modulators (SERM) to aid withdrawal from anabolic steroids<sup>33</sup>. However, there are currently no randomised control studies suggesting whether such treatment can ameliorate symptoms of anabolic androgen withdrawal, or improve the prognosis of successful withdrawal.

## **7. Patient education to support self-management**

All patients should be provided with education about their condition and treatment aiming to improve adherence and optimisation of testosterone treatment. Clinicians should consider the patient's needs and individual preferences when discussing testosterone treatment initiation. Except perhaps in the context of compensated PH, we do not subscribe to the concept of a time-limited "individual therapeutic trial" of testosterone treatment and would expect and encourage any man having a verified diagnosis of hypogonadism to continue treatment lifelong. Non-adherence to testosterone treatment can compromise patients' quality of life, physical and cognitive performance and bone density<sup>19,100,101</sup>. Nevertheless, treatment gaps of more than a year and high discontinuation rates after six months post-testosterone treatment initiation were

reported by 37%<sup>19,102</sup> and 65%<sup>103</sup> of patients, respectively. Similar high discontinuation rates post-testosterone treatment initiation were also reported by Donatucci et al; 52% of patients on daily transdermal testosterone treatment discontinued treatment after 3 months compared to 31% of patients on short-acting testosterone treatment injections, though it should be noted that the latter group did not include patients on long-acting testosterone undecanoate injections and it is not clear if patients who discontinued testosterone treatment switched to another testosterone treatment formulation<sup>104</sup>. The gap between stopping and restarting testosterone treatment tended to decrease over time, suggesting that patients who experienced a benefit from testosterone treatment remained on treatment<sup>104</sup>. Dissatisfaction with the information received about treatment, perceived impaired communication with clinicians, and lack of continuity of care were also reported by patients as significant barriers to treatment non-adherence.<sup>19</sup>. However, one should anticipate high drop-out rates among men without accurately verified hypogonadism started empirical on testosterone treatment for non-specific symptoms and, predictably, achieving little benefit. Individual patient needs will often guide the treatment option for testosterone treatment; factors that influence this are ease of use, ability to raise testosterone levels, improvement in symptoms, convenience, cost, and the patient's preferred route of administration such as topical versus injections<sup>105,106</sup>. Beyond the well-known effects of testosterone treatment on sexual function (which may or may not be relevant to older men), it is important to make them aware of the other long-term health benefits of testosterone treatment, such as on bone and muscle strength<sup>54,83</sup>.

Patient Advocacy Groups (PAG) play an important role in supporting patients with MH. The patient member of The Guideline Committee leads a UK-based PAG and made a significant contribution to these guidelines. His feedback which is summarised in **Box 1**, is based on the shared experiences of PAG members which he is coordinating.

**Insert Box 1 here**



## 8. Cardiovascular and cerebrovascular risk during testosterone therapy

Androgens have an array of reported biological actions including systemic and coronary vasodilation<sup>107</sup>, increase in haematocrit by stimulating erythropoiesis<sup>108</sup>, promotion of platelet aggregation<sup>109</sup>, positively inotropic effects on cardiomyocytes<sup>110</sup> and shortened QT interval on electrocardiogram<sup>111</sup>. Androgens and testosterone treatment are therefore likely to have complex actions on cardiovascular and cerebrovascular risk.

Older men with untreated hypogonadism have increased mortality compared with eugonadal men, even after adjusting for age, study centre, body mass index (BMI), current smoking, and poor general health<sup>112,113</sup>. There is ongoing controversy regarding the effects of testosterone treatment on cardiovascular risk. Indeed, a large multicentre randomised controlled trial (RCT) was stopped early due to an increased rate of adverse cardiovascular events in men aged >65 years taking testosterone treatment<sup>114</sup>; notably many subjects had significant co-morbidities and target serum testosterone levels were set in the top half of the reference range, which may have attributed to the risk of adverse events in this patient group. Other RCTs reported either no effect, or even a reduction in markers of cardiovascular disease<sup>115,116</sup>. testosterone treatment has been reported to increase noncalcified plaque volume and total plaque volume vs. placebo<sup>117</sup>, and is associated with small reductions in LDL, HDL, VLDL cholesterol and fasting insulin<sup>118</sup>. Several systematic reviews have reported on different outcomes using several cardiovascular endpoints in varying patient subgroups<sup>119-122</sup>. Unsurprisingly, their varied conclusions underline the current lack of consensus regarding the clinical effectiveness and safety of testosterone treatment in symptomatic men with low testosterone. The NIH testosterone (T) trials provided the largest RCT data of testosterone treatment in men with MH<sup>52</sup>. A highly selected group of 790 men, 65 years of age or older, with a serum testosterone concentration  $\leq 275$  ng/dL (9.535 nmol/L), excluding men with PH, and symptoms suggesting

hypogonadism were randomly assigned to receive either testosterone gel or placebo gel for 1 year<sup>52</sup>. Though not powered to investigate the safety of testosterone treatment, the NIH T trials reported that a total of 14 men had myocardial infarction, stroke, or death from cardiovascular causes; 7/14 (50%) of these men received placebo<sup>52</sup>. The US Federal Drugs Administration (FDA) recommends that men on testosterone treatment be advised of the potential cardiovascular risks<sup>123</sup>, whereas the European Medicines Agency (EMA) considers that there is insufficient evidence to link testosterone treatment with increased cardiovascular risk<sup>124</sup>.

Two ongoing projects may help to elucidate the safety of testosterone treatment. Firstly, the NIHR Testosterone and Efficacy & Safety (TestES) consortium is an individual patient data (IPD) meta-analysis pooling patient level adverse event data from individual RCTs<sup>125</sup>.

Secondly, the US-led TRAVERSE trial is currently enrolling 6000 men aged 45–80 years with serum testosterone levels <300ng/dL and high cardiovascular risk to random allocation of testosterone gel or placebo for five years<sup>126</sup>. Additionally, published data from studies involving transgender men and women clearly show an increased risk of cardiovascular disease with oestrogen treatment in transwomen, but not from testosterone treatment in transmen, although these individuals were young and therefore at low background risk<sup>127,128</sup>.

A recent observational study suggested that in men with or without hypogonadism, testosterone treatment was associated with increased risk of venous thrombo-embolism (VTE) (age-adjusted odds ratios 2.32 and 2.02, respectively) when compared with men not taking testosterone treatment<sup>129</sup>. Men with obesity, for whom lifestyle change likely represented a better intervention anyway, were at higher risk of VTE in this study, and the highest overall risk was observed during the first six months of treatment. Clinicians should therefore counsel men that testosterone treatment can increase the risk of thrombosis, although the absolute risk is low and can probably be mitigated by ensuring that haematocrit remains physiological. When haematocrit is elevated >0.5, testosterone treatment should be adjusted according to the

treatment formulation, by either lowering the dose of the daily transdermal testosterone treatment, by extending the interval periods between testosterone injections, or by switching to transdermal testosterone treatment which may have a lower risk of erythrocytosis compared to with injectable testosterone treatment<sup>130</sup>. Secondary causes of elevated haematocrit should also be investigated and, when haematocrit remains markedly elevated, testosterone treatment should be stopped and haematological advice urgently sought.

In summary, the available RCT and observational data fail to reveal any consistent association (positive or negative) between testosterone treatment and cardiovascular and cerebrovascular events. Therefore, we conclude that testosterone treatment has uncertain effects on cardiovascular and cerebrovascular risk. However, further data are likely to become available soon, which will provide a more secure evidence base in respect of cardiovascular risk or safety for clinicians prescribing testosterone treatment to men with hypogonadism. Meanwhile, clinicians are advised to consider cardiovascular risk in men before initiating testosterone treatment; in men with high cardiovascular risk, we recommend counselling them that the cardiovascular safety of testosterone therapy remains uncertain

## **9. Effects on bone mineral density**

Hypogonadism causes reductions in bone mineral density (BMD), while testosterone treatment increases both vertebral and femoral BMD<sup>131</sup>. Currently, there are no data from which to determine whether testosterone treatment reduces fracture risk in men with hypogonadism, although this is assumed to be likely. In men with hypogonadism and reduced BMD, consider repeating BMD assessment at an appropriate interval after commencement of testosterone therapy. testosterone treatment is not indicated for treatment of osteoporosis in the absence of MH. For older men with MH having established osteoporosis and already at high risk of fracture, bone-specific drugs should be considered in addition to testosterone treatment.

However, for younger men with MH, it is more logical to defer consideration of bone-specific drugs until testosterone treatment-induced improvements in BMD have plateaued. At that point, if osteoporosis is still present, then bone-specific drugs can be added to testosterone treatment. However, hard data are lacking.

## **10. Screening for prostate cancer in men during testosterone therapy**

Prostate cancer is the most common non-dermatological cancer and the second leading cause of cancer death in men in Europe and North America<sup>132</sup>. Prostate cancer primarily affects older men. It is therefore not surprising that many older men are at risk of both male hypogonadism and prostate cancer. Androgen hormones are trophic to prostate tissue, and androgen deprivation therapy is routinely used for the treatment of prostate cancer.

### *10.1. Testosterone therapy in men without prostate cancer*

Circulating levels of testosterone are correlated with serum PSA in hypogonadism; however, there is no statistical relationship with PSA in eugonadal men (*the saturation hypothesis*)<sup>133</sup>. A systematic review suggested that testosterone treatment does not increase the subsequent risk of prostate cancer in men without prior disease<sup>134</sup>. Furthermore, a Canadian study on 12,779 men with new hypogonadism found that during 58,224 person-years of follow-up, use of testosterone treatment was not associated with an overall increased risk of prostate cancer (hazard ratio 0.97; 95%CI 0.71-1.32)<sup>135</sup>. For these reasons, it is generally accepted that testosterone treatment does not increase the risk of developing new prostate cancer. However, there is a physiological restoration of prostate size after initiation of testosterone treatment in men with MH which may unmask *incidental* problems. It is important to ask men with MH about the occurrence of urinary symptoms within the first few months following testosterone treatment initiation; those symptoms should be investigated according to routine practice.

Historically, prostate cancer screening has been conducted during testosterone treatment, in the form of serum PSA measurement and digital rectal examination (DRE) (since 1% of prostate cancers are non-PSA-secreting). However, endocrinologists generally have no experience recognising the features of prostate cancer during DRE, which makes this practice likely to be ineffective and potentially harmful. Major risk factors for prostate cancer are increased age, black ethnicity and family history, and all men (regardless of testosterone treatment) should undergo screening according to local practice. Theoretically, prostate screening might exclude a pre-existing tumour during testosterone treatment, but there is insufficient evidence to support the efficacy or safety of such an approach. In the absence of robust evidence, we do not recommend that mandatory screening for prostate cancer be performed during testosterone treatment.

#### *10.2. Testosterone therapy in men with prostate cancer*

A recent systematic review of 36 studies including 2,459 testosterone-treated patients found that testosterone treatment is not associated with increased risk of disease progression in prostate cancer<sup>136</sup>. The quality of studies included was poor though, with no level 1 evidence. Also, this review suggested that testosterone treatment might be harmful in men with metastatic prostate cancer (progression rate: 38.5%-100.0%), those undergoing active surveillance for low-risk localised prostate cancer (15.4-57.1%), and those with high-risk prostate cancer who were successfully treated (0.0%-50.0%). Joint management with a urologist is mandatory in men with known prostate cancer (treated or untreated), to monitor PSA and where necessary, conduct imaging with MRI, PSMA-PET, or CT/bone scan based on PSA kinetics and the clinical state of the patient. For those men with untreated prostate cancer (for example those for conservative management / surveillance) monitoring will be more intense and a multi-disciplinary decision between patient, urologist/uro-oncologist, and endocrinologist should be

made regarding risks *versus* benefit for testosterone treatment. Any changes on surveillance MRI imaging, PSA kinetics, or development of prostate cancer-associated symptoms will usually be an indication to cease testosterone treatment.

It is important to note that these recommendations are expert opinion based on the best available evidence, and that there remains significant uncertainty about screening for prostate cancer in the general population, albeit even more so in men on testosterone treatment. Our recommendations thus offer a pragmatic solution to a problem whose precise dimensions are unknown. It is hoped that these recommendations can be tailored in future based on RCTs examining prostate cancer risk in men on testosterone treatment and especially those with risk factors based on age, family history, and ethnicity.

## **11. Fertility considerations for testosterone therapy**

### *11.1. Fertility in men with MH*

Fertility is initiated at puberty, secondary to the rise in GnRH/gonadotrophin secretion and increasing testosterone production by the testis. It is well established that optimal normal spermatogenesis requires both FSH and testosterone, but there is a lack of a clear dose-dependency for both these trophic factors. Testosterone concentrations in the testis are approx. 100-fold higher than in the circulation and this is essential for the paracrine action of testosterone on Sertoli cells to support spermatogenesis. Thus, intratesticular or paracrine testosterone deficiency sufficient to impact on spermatogenesis is not a consideration where there is ongoing LH secretion and functional Leydig cells. However, classical hypogonadal pathologies are important causes of infertility, e.g. Klinefelter syndrome, Kallmann syndrome, hypopituitarism. Where the pathology is in the hypothalamus or pituitary causing CH, there is the potential for successful endocrine treatment. Obesity is also associated with CH<sup>137</sup>. Although spermatogenesis is dependent on LH and FSH, there are no accurate cut-off levels

for either parameter in CHH that usefully predict male infertility or disordered spermatogenesis, so a semen analysis should be obtained whenever fertility needs to be assessed. Men with normal or elevated gonadotrophin levels (or an isolated elevation of FSH) do not benefit from gonadotrophin therapy, or indeed any other medical therapy, to stimulate spermatogenesis or improve fertility and assisted reproduction will often be required.

### *11.2. Impact of testosterone therapy on fertility*

Exogenous testosterone will suppress gonadotrophin secretion and thus spermatogenesis, and indeed this is the basis for the development of hormonal male contraception. Conversely it cannot be assumed that testosterone treatment will cause infertility, and contraception should always be discussed and advised where appropriate. Fertility intentions should be explicitly discussed with the patient whenever testosterone treatment is being considered, and the likely time needed for induction of spermatogenesis (see below). Patients with CH can, however, be reassured that testosterone treatment does not negatively impact the chances of success from subsequent gonadotrophin therapy<sup>20</sup>.

### *11.3. Treatment of subfertility in men with MH*

Subfertility should be investigated with physical examination for signs of hypogonadism, semen analysis (with a second sample if the first is abnormal), complemented with measurement of LH, FSH and testosterone prior to initiating testosterone treatment. Fertility may benefit from lifestyle factors such as balanced diet and smoking cessation. In the situation of a heterosexual relationship, it is always essential to consider the fertility status and age of the female partner in order to establish the prospects for successful conception (whether natural or assisted) and pregnancy prior to starting treatment for the male partner. In men with CH, the considerations are starting human chorionic gonadotrophin (hCG), FSH, or both. Pulsatile

GnRH therapy might be used in men with normal pituitary function but is not widely available. hCG can be considered an LH-mimetic, with very high potency and long half-life compared to LH. Administration is with the aim of stimulating the Leydig cells of the testis and thus stimulating endogenous testosterone production: it is therefore only of value when there is clear-cut LH and testosterone deficiency. Very low doses of hCG (125 IU) will restore intratesticular testosterone concentration <sup>138</sup>, while higher doses are required to normalise circulating testosterone concentrations. A conventional starting dose is 1000-1500 IU sc twice a week, with a check of FBC, testosterone and oestradiol levels after 4 weeks. The dose can be increased to 2,500 IU twice or thrice-weekly, with higher doses rarely required or being effective; a high serum oestradiol level signposting risk of gynaecomastia may suggest reduction of the hCG dose. Unfortunately, there are currently no hCG products with marketing authorisation in the UK, so the choice lies between one having UK and European marketing authorisation for women only, or one that has marketing authorisation for use in males in certain European countries, but not yet in the UK. One possibility is to use Ovitrelle®, which is a prefilled pen-type injector containing 10,000 IU recombinant hCG marketed for IVF in women. The dose is adjustable according to the number of ‘clicks’ on twisting the barrel, but there are no marked gradations. **Table 3** indicates the dose according to the number of clicks, but it is important to recognise that this is empirical. We do not endorse combination therapy with both hCG and testosterone in men with MH

**Insert Table 3 here**

hCG alone may be enough to restore spermatogenesis in men with CH of post-pubertal onset, e.g. after pituitary surgery <sup>139</sup>. This may reflect some remaining FSH secretion, albeit at low levels. Post-pubertal stimulation of spermatogenesis can be successfully achieved more often than where there has not been pubertal development (84% vs 68%), and with higher sperm



concentrations achieved<sup>20</sup>. Similarly, a second course of gonadotrophin therapy will stimulate spermatogenesis faster than the first course. Regarding FSH administration, the issues are whether it is required, and when to initiate it. As described above, men with adult-onset CH may not require it. It is however almost invariably required in men with congenital/prepubertal CH, in whom both FSH and hCG therapy should be initiated simultaneously at the outset. The historic approach was to add FSH after 6 months treatment with hCG if the man remained azoospermic, but in fact men with congenital/prepubertal hypogonadotrophism hardly ever achieve meaningful spermatogenesis with hCG monotherapy, even when prolonged for up to 10 years<sup>140</sup> and so this hCG-first regimen is logically reserved for men with CH acquired post-pubertally. A dose of 75-300 IU sc three times per week is used, thus the patient also receiving hCG will require to self-inject 5 times per week, potentially for many months. FSH levels can be measured on treatment and a physiological target range 4 to 8 IU/L is advisable<sup>141</sup>. The long-acting FSH analogue corifollitrophin alpha requires administration every 2 weeks, and while there is evidence of efficacy in this indication<sup>142</sup>, it is not widely used.

It has been postulated that in men with the most severe form of congenital CH (testicular volume < 4 ml), pre-treatment with FSH for several months before adding hCG may improve subsequent spermatogenesis, but the evidence is limited albeit the scientific basis appears sound<sup>141</sup>. Moreover, FSH monotherapy necessarily prolongs untreated hypogonadism unless exogenous testosterone is also given. Prior administration of androgens has been shown in a meta-analysis and subsequent RCT not to result in a slower response to gonadotrophin therapy<sup>20,143</sup>.

Repeat semen analysis should be performed 3 months after initiating treatment, and at 3-month intervals thereafter. Baseline testicular volume, pubertal status and a history of cryptorchidism are indicators of time to respond, but fertility may be achieved even with a history of bilateral testicular maldescent<sup>144-146</sup>. Patients should be clearly counselled at the start about the likely

prolonged duration of treatment; however, it is important to recognise that fertility may be achieved with very low sperm concentrations, and conventionally normal sperm concentrations will not be achieved in many men. A meta-analysis indicated that a mean sperm concentration of 5.2 million/ml (95%CI 4.7-7.1) was achieved by gonadotrophin therapy <sup>20</sup>, with a median time to achieve sperm in the ejaculate of 7.1 months (95% CI 6.3-10.1) and to conception of 28.2 months (21.6-38.5) <sup>145</sup>. The need for protracted treatment and the anticipated production of low numbers of sperm (but seemingly of high quality) should be carefully considered to prevent premature recourse to assisted reproduction, but conversely the age of the female partner may also be a factor in when that becomes appropriate. *i.e.* when the female partner is in her late 30s, prompt recourse to assisted reproductive technology (ART) would be wise from the moment that sperm appear in the ejaculate.

Once pregnancy is established, there are the following options:

- Revert to or initiate testosterone therapy;
- If the couple are considering a second child, it is possible to stop FSH and continue with hCG alone. This will maintain testosterone production and continue to support some degree of spermatogenesis: at the time a further pregnancy is desired, FSH may be restarted if indicated by repeat semen analysis;
- If there is concern over testicular function (e.g. if only a very low sperm concentration has been achieved, and ICSI was required) embryo (where available) and sperm cryopreservation should be considered.

- In the UK, patients generally have good access to testosterone treatment
- A wide variation exists in the follow-up testing of patients, including the availability of bone densitometry
- Improved awareness of the different needs of various patients on testosterone treatment is required
- For some patients, blood testing is not done in a timely manner, *e.g.* at the end of a long acting testosterone IM injection, which can result in weeks of low testosterone before the patient received their next injection.

Patients on long term therapy have symptomatic awareness of abnormalities in their testosterone levels, which can be very useful to monitor and can be used as a guide even in the absence of blood test results. Active communication between the patient and health care provider is crucial to optimising testosterone treatment and avoid over- or under-replacement. Engaging with the patient is particularly important in the rarer forms of male hypogonadism where different treatment protocols may be more appropriate.

Some patients may be hesitant about starting or continuing testosterone treatment as they are unaware of all the treatment benefits and may be concerned about side effects, which can have a negative impact on adherence to treatment. Clinicians are advised to make patients aware of all possible testosterone treatments and differences in approach regarding monitoring and to support them to select the most suitable treatment for their needs.

| Congenital disorders                        | Acquired diseases                                     |
|---|---|
| <b>Primary Gonadal Insufficiency</b>        |   |
| Klinefelter syndrome                        | Gonadectomy - bilateral                               |
| uncorrected bilateral Cryptorchidism        | Trauma or Torsion - bilateral                         |
| Testicular regression (vanishing testes)    | Orchitis - bilateral                                  |
| Partial Androgen Insensitivity syndrome     | Chemotherapy - alkylating                             |
| inactivating LHCG receptor mutations        | Radiotherapy - pelvic                                 |
| Congenital adrenal hyperplasia              | Ageing and age-associated co-morbidities              |
|   | Heavy Tobacco smoking                                 |
|   | Chronic alcohol abuse                                 |
|   | Systemic diseases:                                    |
|   | - HIV infection                                       |
|   | - Sickle cell disease                                 |
|   | - Coeliac disease                                     |
|   | - Uraemia   |
| <b>Central Hypogonadism</b>                 |   |
| Isolated GnRH deficiency                    | Parasellar tumours, especially prolactinoma           |
| - Kallmann syndrome                         |   |
| - normosmic Congenital HH                   | Inflammatory/Infiltrative diseases                    |
|   | - sarcoidosis   |
| Syndromic forms of GnRH deficiency :        | - histiocytosis                                       |
| - Combined Pituitary Hormone deficiency     | - Iron overload, <i>e.g.</i> genetic Haemochromatosis |
| - Septo-Optic Dysplasia                     |   |
| - CHARGE syndrome                           | Trauma / Vascular / Radiation                         |
| - Bardet-Biedl syndrome?                    | - military blast trauma                               |
| - Prader-Willi syndrome                     | - pituitary Apoplexy or Stalk transection             |
| - <i>Adrenohypoplasia Congenita (NROB1)</i> | - cranial Surgery & Irradiation                       |
| - leptin deficiency / leptin resistance     |   |
|   | Drug-induced  |
|   | - Opioids & Narcotics                                 |
|   | - high-dose Glucocorticoids                           |
|   | - Androgen Deprivation Therapy                        |
|   | - Anti-dopaminergic Antipsychotics                    |
|   | - Cannabinoids  |
|   | - Androgenic anabolic steroids                        |
|   | - Estrogens   |
|   | -   |

**Table 2: Testosterone therapy formulations and their characteristics.** T – Testosterone.

| Formulation and dose  | Administration & monitoring   | Advantages   | Disadvantages   |
|---|---|--|---|
| <b>Transdermal topical T gels and axillary solution</b><br>50–100 mg of 1% Testogel®, 40–70 mg of 2% Tostran®, 23–46 mg of Testavan® or 20.25–81 mg of 16.2mg/g (Testogel® pump) transdermal gel once daily<br>60 mg of T solution applied in the axillae once daily (not available in the UK)              | Clear alcohol gel available in sachets, tubes and pumps containing, applied dry, clean skin on shoulders, abdomen, upper arms or thighs (avoid genital area).<br>Monitor total T 2–6 hours post-gel application, 2–3 weeks post-treatment initiation or dose adjustment, aiming for mid-normal reference range total T.   | Convenient, flexible and easy application; good skin tolerability. Effective, provides T levels within normal range for 24 h. Steady physiological levels of serum T with no “peak & troughs” between applications. Dose easily adjustable to individual needs. No pain of injections.     | May cause skin dryness and irritation for some patients. Takes time to apply. Potential of transfer to a female partner or child by direct skin-to-skin contact. Fear of transfer may inhibit intimacy; patient education minimises potential of transfer. Increased DHT levels due to presence of 5 $\alpha$ -reductase in the skin. Considerable inter- and intra-individual T levels require close dose titration. |
| <b>Long-acting T undecanoate IM injections</b><br>1000 mg in 4 mL (Nebido®) ampoule of oily preparation every 10–14 weeks   | Injected slowly deep into the gluteal muscle. The second injection (loading dose) is given at 6 weeks, and the third dose 12-weeks after the second. Injection interval is adjusted based on trough total T level just before the third injection, aiming for lower end of normal reference range level. Monitor trough total T and FBC every 3–5 injections or annually. | Effective, maintains physiological serum T levels for 3 months or longer. Smoother serum T profile compared to short-acting T injections, with less noticeable “peak and trough” symptoms. Convenient, 3-monthly administration without the side effects seen with T implants.             | Pain, discomfort and adverse reaction at injection site. Requires large muscle bulk for injection. Lifestyle restrictions as it cannot be self-administered. Not recommended as first-line treatment option due to inability of withdrawal in case of adverse events (AE). Rare AE of pulmonary micro-embolism presenting with severe coughing episode during injection.  |
| <b>Short-acting T injections</b><br>1. Combination of testosterone esters 250 mg/mL (Sustanon®) IM every 3–4 weeks (propionate 30 mg, phenylpropionate 60 mg, isocaproate 60 mg, decanoate 100 mg);<br>2. Testosterone enanthate or cypionate 150–200 mg IM every 2 weeks or 50–100 mg IM or SC once a week | Oily preparation (1 mL) injected slowly into the gluteal muscle or upper thigh. Adjust injection interval based on trough total T level at the end of the injection aiming for lower end of normal reference range. Monitor trough total T and FBC every 6–12 months.   | Dose flexibility and convenient administration, relatively inexpensive. Improves symptoms of androgen deficiency; mostly noticeable in the first days after the injection. SC injection has comparable pharmacokinetics, safety and tolerability to IM injection and can be self-injected. | Potentially unpleasant “peak & trough” symptoms due to supraphysiological T levels post-injection which decline to hypogonadal range by the next injection. Risk of polycythaemia due to supraphysiological T levels. Pain, discomfort at injection site. Lifestyle restrictions for patients not self-injecting.   |

|   |  |  |  |
|---|--|--|--|
| <b>Bio-adhesive Buccal T tablet</b><br><i>30 mg controlled-release tablets applied to the upper gum twice daily (not available in the UK)</i> | T is absorbed gradually from the buccal mucosa over 12 h. Applied on healthy, clean gum; the solid tablet softens and moulds to the shape of the gum. Monitor T 2-6 hours post-tablet application, 2-3 weeks post-treatment initiation, aiming for mid-normal reference range total T. | Easy and fast to apply; Effective; serum T levels remain within physiological range with twice daily application without significant peaks and troughs; “easy to remember” administration with teeth brushing daily routine. | Risk of gum-related adverse events reported by 16% of treated men. May detach when eating shortly after application. Takes time to get used to; patient education is vital for medication adherence. |
| <b>Subcutaneous T implants</b><br><i>Testosterone pellets 100 or 200 mg to a total of 600–1200 mg T per dose (rarely administered)</i>        | 3–6 pellets every 4–6 months. Pellets implanted in the subcutaneous adipose tissue with surgical incision under local anaesthetic.   | Serum T peaks at 1 month and is sustained in normal range for up to 6 months. Convenience—twice or thrice a year application.  | Painful procedure with high risk of infection at the insertion point and scar tissue. Risk of spontaneous extrusion after implantation.  |
| <b>Oral T undecanoate capsules 40 mg</b><br><i>1–3 capsules (40–120 mg) twice or thrice daily with meals</i>                                  | Taken orally; absorption is improved when taken with fatty meal. Swallow without chewing.  | Easy and convenient administration. Suitable for patients who cannot tolerate other forms of treatment and those who require low levels of T, not a preferred treatment option.  | Low bioavailability and very high inter- and intra-individual variability in absorption resulting in insufficient serum T levels. Normal serum T level attained for only up to 3–5 h.                |

983

984

985

986

**Table 3:**


**Dosing using prefilled Ovitrelle® (human chorionic gonadotrophin, hCG) 6,500 IU pen**

| Ovitrelle® dose (IU) | No of clicks (calculated dose, IU) |
|----------------------|------------------------------------|
| 1500                 | 6 (1560)                           |
| 2000                 | 8 (2080)                           |
| 2500                 | 10 (2600)                          |
| 3000                 | 12 (3120)                          |
| 4000                 | 15 (3900)                          |
| 5000                 | 19 (4950)                          |

987 **Figure 1: Flowchart for male hypogonadism management**

988 MH, male hypogonadism; TT, total testosterone; LH, luteinising hormone; SHBG, sex hormone binding globulin; CH, central hypogonadism; NGI, non-  
989 gonadal illness; BMD, bone mineral density; ED, erectile dysfunction

**Figure 1**





991     **References**

- 992     1.       Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An  
993            Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2018;103(5):1715-1744.
- 994     2.       Khera M, Broderick GA, Carson CC, 3rd, et al. Adult-Onset Hypogonadism. *Mayo Clin Proc.*  
995            2016;91(7):908-926.
- 996     3.       Salvi R, Pralong FP. Molecular characterization and phenotypic expression of mutations in genes for  
997            gonadotropins and their receptors in humans. *Front Horm Res.* 2010;39:1-12.
- 998     4.       Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's  
999            syndrome and is associated with abdominal obesity and hypogonadism. *Diabetes Care.*  
1000           2006;29(7):1591-1598.
- 1001   5.       Dahlqvist JR, Vissing J. Diabetes in myotonic dystrophy. In: *Diabetes Associated with Single Gene*  
1002            *Defects and Chromosomal Abnormalities.* Vol 25. Karger Publishers; 2017:182-187.
- 1003   6.       Cheng J, Han B, Li Q, et al. Testosterone: Relationships with Metabolic Disorders in Men-An  
1004            Observational Study from SPECT-China. *International journal of endocrinology.* 2017;2017:4547658-  
1005            4547658.
- 1006   7.       Lee PA, Houk CP. Cryptorchidism. *Curr Opin Endocrinol Diabetes Obes.* 2013;20(3):210-216.
- 1007   8.       Ritzen EM, Bergh A, Bjerknes R, et al. Nordic consensus on treatment of undescended testes. *Acta*  
1008            *Paediatr.* 2007;96(5):638-643.
- 1009   9.       Chan E, Wayne C, Nasr A, Resource FfCAoPSE-B. Ideal timing of orchiopexy: a systematic review.  
1010            *Pediatr Surg Int.* 2014;30(1):87-97.
- 1011   10.      Juul A, Almstrup K, Andersson AM, et al. Possible fetal determinants of male infertility. *Nature*  
1012            *reviews Endocrinology.* 2014;10(9):553-562.
- 1013   11.      Groth KA, Skakkebaek A, Høst C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a  
1014            clinical update. *J Clin Endocrinol Metab.* 2013;98(1):20-30.
- 1015   12.      Skakkebaek A, Wallentin M, Gravholt CH. Neuropsychology and socioeconomic aspects of  
1016            Klinefelter syndrome: new developments. *Curr Opin Endocrinol Diabetes Obes.* 2015;22(3):209-216.
- 1017   13.      Turrieff A, Levy HP, Biesecker B. Factors associated with adaptation to Klinefelter syndrome: the  
1018            experience of adolescents and adults. *Patient education and counseling.* 2015;98(1):90-95.
- 1019   14.      Ross A, Bhasin S. Hypogonadism: Its Prevalence and Diagnosis. *The Urologic clinics of North*  
1020            *America.* 2016;43(2):163-176.

- 1021 15. Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated  
1022 hypogonadism in aging men: evidence from the European Male Ageing Study. *J Clin Endocrinol*  
1023 *Metab.* 2010;95(4):1810-1818.
- 1024 16. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus  
1025 Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment.  
1026 *Nature reviews Endocrinology.* 2015;11(9):547-564.
- 1027 17. Stamou MI, Cox KH, Crowley WF, Jr. Discovering Genes Essential to the Hypothalamic Regulation of  
1028 Human Reproduction Using a Human Disease Model: Adjusting to Life in the "-Omics" Era.  
1029 *Endocrine reviews.* 2015;36(6):603-621.
- 1030 18. Cangiano B, Swee DS, Quinton R, Bonomi M. Genetics of congenital hypogonadotropic  
1031 hypogonadism: peculiarities and phenotype of an oligogenic disease. *Hum Genet.* 2021;140(1):77-  
1032 111.
- 1033 19. Dwyer A, Quinton R, Morin D, Pitteloud N. Identifying the unmet health needs of patients with  
1034 congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for  
1035 online interventions and peer-to-peer support. *Orphanet journal of rare diseases.* 2014;9:83.
- 1036 20. Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-  
1037 replacement therapy: a meta-analytic study. *Andrology.* 2014;2(6):794-808.
- 1038 21. Dwyer AA, Raivio T, Pitteloud N. MANAGEMENT OF ENDOCRINE DISEASE: Reversible  
1039 hypogonadotropic hypogonadism. *European journal of endocrinology / European Federation of*  
1040 *Endocrine Societies.* 2016;174(6):R267-274.
- 1041 22. Brioude F, Bouligand J, Trabado S, et al. Non-syndromic congenital hypogonadotropic  
1042 hypogonadism: clinical presentation and genotype-phenotype relationships. *European journal of*  
1043 *endocrinology / European Federation of Endocrine Societies.* 2010;162(5):835-851.
- 1044 23. Mao J, Xu H, Wang X, et al. Congenital combined pituitary hormone deficiency patients have better  
1045 responses to gonadotrophin-induced spermatogenesis than idiopathic hypogonadotropic  
1046 hypogonadism patients. *Hum Reprod.* 2015;30(9):2031-2037.
- 1047 24. Castinetti F, Reynaud R, Saveanu A, et al. MECHANISMS IN ENDOCRINOLOGY: An update in the  
1048 genetic aetiologies of combined pituitary hormone deficiency. *European journal of endocrinology /*  
1049 *European Federation of Endocrine Societies.* 2016;174(6):R239-247.
- 1050 25. Ryabets-Lienhard A, Stewart C, Borchert M, Geffner ME. The Optic Nerve Hypoplasia Spectrum:  
1051 Review of the Literature and Clinical Guidelines. *Advances in pediatrics.* 2016;63(1):127-146.

- 1052 26. Raivio T, Avbelj M, McCabe MJ, et al. Genetic overlap in Kallmann syndrome, combined pituitary  
1053 hormone deficiency, and septo-optic dysplasia. *J Clin Endocrinol Metab.* 2012;97(4):E694-699.
- 1054 27. Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, van Ravenswaaij-Arts CM. CHD7  
1055 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. *J Med*  
1056 *Genet.* 2011;48(5):334-342.
- 1057 28. Khan SA, Muhammad N, Khan MA, Kamal A, Rehman ZU, Khan S. Genetics of human Bardet-Biedl  
1058 syndrome, an updates. *Clin Genet.* 2016;90(1):3-15.
- 1059 29. Kosciński I, Mark M, Messaddeq N, et al. Reproduction Function in Male Patients With Bardet Biedl  
1060 Syndrome. *The Journal of Clinical Endocrinology & Metabolism.* 2020;105(12):e4417-e4429.
- 1061 30. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and  
1062 endocrine findings. *Journal of endocrinological investigation.* 2015;38(12):1249-1263.
- 1063 31. Deal CL, Tony M, Hoybye C, et al. GrowthHormone Research Society workshop summary:  
1064 consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. *J*  
1065 *Clin Endocrinol Metab.* 2013;98(6):E1072-1087.
- 1066 32. Jadhav U, Harris RM, Jameson JL. Hypogonadotropic hypogonadism in subjects with DAX1  
1067 mutations. *Mol Cell Endocrinol.* 2011;346(1-2):65-73.
- 1068 33. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism:  
1069 diagnosis and treatment. *Fertil Steril.* 2014;101(5):1271-9.
- 1070 34. Christou MA, Tigas S. Recovery of reproductive function following androgen abuse. *Curr Opin*  
1071 *Endocrinol Diabetes Obes.* 2018;25(3):195-200.
- 1072 35. Rasmussen JJ, Albrethsen J, Frandsen MN, Jørgensen N, Juul A, Kistorp C. Serum Insulin-like Factor  
1073 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity. *The*  
1074 *Journal of Clinical Endocrinology & Metabolism.* 2021;106(7):e2664-e2672.
- 1075 36. Nachtigall LB, Boepple PA, Pralong FP, Crowley WF, Jr. Adult-onset idiopathic hypogonadotropic  
1076 hypogonadism--a treatable form of male infertility. *The New England journal of medicine.*  
1077 1997;336(6):410-415.
- 1078 37. Dwyer AA, Hayes FJ, Plummer L, Pitteloud N, Crowley WF, Jr. The long-term clinical follow-up and  
1079 natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. *J Clin*  
1080 *Endocrinol Metab.* 2010;95(9):4235-4243.
- 1081 38. De Maddalena C, Bellini M, Berra M, Meriggiola MC, Aloisi AM. Opioid-induced hypogonadism: why  
1082 and how to treat it. *Pain physician.* 2012;15(3 Suppl):ES111-118.

- 1083 39. Fourman LT, Fazeli PK. Neuroendocrine causes of amenorrhea--an update. *J Clin Endocrinol Metab.*  
1084 2015;100(3):812-824.
- 1085 40. Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. *The*  
1086 *New England journal of medicine.* 2011;364(3):215-225.
- 1087 41. Delaney A, Burkholder AB, Lavender CA, et al. Increased Burden of Rare Sequence Variants in  
1088 GnRH-Associated Genes in Women With Hypothalamic Amenorrhea. *J Clin Endocrinol Metab.*  
1089 2021;106(3):e1441-e1452.
- 1090 42. Chavan N, Dwyer A, KW. K, et al. Male functional hypogonadotropic hypogonadism: A distinct  
1091 clinical entity? Abstract presented at 92nd Annual Meeting of the Endocrine Society; 2010; San  
1092 Diego, USA.
- 1093 43. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review.  
1094 *Psychosomatics.* 2014;55(1):29-36.
- 1095 44. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. *Endocrinology and*  
1096 *metabolism clinics of North America.* 2007;36(2):333-348.
- 1097 45. Turner HE, Wass JA. Gonadal function in men with chronic illness. *Clinical endocrinology.*  
1098 1997;47(4):379-403.
- 1099 46. Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine's Process of  
1100 Care for the Assessment and Management of Testosterone Deficiency in Adult Men. *J Sex Med.*  
1101 2015;12(8):1660-1686.
- 1102 47. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and  
1103 elderly men. *The New England journal of medicine.* 2010;363(2):123-135.
- 1104 48. Kelly DM, Jones TH. Testosterone and obesity. *Obesity reviews : an official journal of the*  
1105 *International Association for the Study of Obesity.* 2015;16(7):581-606.
- 1106 49. Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-  
1107 testicular function in middle-aged and older men are modified by weight change and lifestyle  
1108 factors: longitudinal results from the European Male Ageing Study. *European journal of*  
1109 *endocrinology / European Federation of Endocrine Societies.* 2013;168(3):445-455.
- 1110 50. Lotti F, Marchiani S, Corona G, Maggi M. Metabolic Syndrome and Reproduction. *International*  
1111 *Journal of Molecular Sciences.* 2021;22(4):1988.
- 1112 51. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Archives of disease*  
1113 *in childhood.* 1970;45(239):13-23.

- 1114 52. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. *The*  
1115 *New England journal of medicine*. 2016;374(7):611-624.
- 1116 53. Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: A Review and Comparison of Current  
1117 Guidelines. *J Sex Med*. 2019;16(6):812-820.
- 1118 54. Al-Sharefi A, Wilkes S, Jayasena CN, Quinton R. How to manage low testosterone level in men: a  
1119 guide for primary care. *Br J Gen Pract*. 2020;70(696):364-365.
- 1120 55. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone  
1121 Levels in Men of Four Cohort Studies in the United States and Europe. *J Clin Endocrinol Metab*.  
1122 2017;102(4):1161-1173.
- 1123 56. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical  
1124 measurement of serum testosterone and other sex hormone levels in men. *J Clin Endocrinol Metab*.  
1125 2009;94(3):907-913.
- 1126 57. Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The efficacy and adverse events of  
1127 testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of  
1128 randomized, placebo-controlled trials. *J Clin Endocrinol Metab*. 2018.
- 1129 58. Wittert G, Atlantis E, Allan C, et al. Testosterone therapy to prevent type 2 diabetes mellitus in at-  
1130 risk men (T4DM): Design and implementation of a double-blind randomized controlled trial.  
1131 *Diabetes Obes Metab*. 2019;21(4):772-780.
- 1132 59. UKNEQAS. Unpublished data from the United Kingdom National External Quality Assessment  
1133 Service (UKNEQAS). Available via: <https://uknegas.org.uk/>. [Accessed on 19<sup>th</sup> May 2021].
- 1134 60. Adaway J, Keevil B, Miller A, Monaghan PJ, Merrett N, Owen L. Ramifications of variability in sex  
1135 hormone-binding globulin measurement by different immunoassays on the calculation of free  
1136 testosterone. *Ann Clin Biochem*. 2020;57(1):88-94.
- 1137 61. Fiers T, Wu F, Moghetti P, Vanderschueren D, Lapauw B, Kaufman JM. Reassessing Free-  
1138 Testosterone Calculation by Liquid Chromatography-Tandem Mass Spectrometry Direct Equilibrium  
1139 Dialysis. *J Clin Endocrinol Metab*. 2018;103(6):2167-2174.
- 1140 62. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A Reappraisal of  
1141 Testosterone's Binding in Circulation: Physiological and Clinical Implications. *Endocrine reviews*.  
1142 2017;38(4):302-324.
- 1143 63. Hackbarth JS, Hoyne JB, Grebe SK, Singh RJ. Accuracy of calculated free testosterone differs  
1144 between equations and depends on gender and SHBG concentration. *Steroids*. 2011;76(1-2):48-55.

- 1145 64. Handelsman DJ. Free Testosterone: Pumping up the Tires or Ending the Free Ride? *Endocrine*  
1146 *reviews*. 2017;38(4):297-301.
- 1147 65. Heinrich-Balard L, Zeinyeh W, Déchaud H, et al. Inverse relationship between hSHBG affinity for  
1148 testosterone and hSHBG concentration revealed by surface plasmon resonance. *Mol Cell*  
1149 *Endocrinol*. 2015;399:201-207.
- 1150 66. Ho CK, Stoddart M, Walton M, Anderson RA, Beckett GJ. Calculated free testosterone in men:  
1151 comparison of four equations and with free androgen index. *Ann Clin Biochem*. 2006;43(Pt 5):389-  
1152 397.
- 1153 67. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. *Clinical*  
1154 *endocrinology*. 2010;73(3):382-388.
- 1155 68. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of  
1156 variability in calculated free testosterone estimates. *Ann Clin Biochem*. 2009;46(Pt 2):137-143.
- 1157 69. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation  
1158 of free testosterone in serum. *J Clin Endocrinol Metab*. 1999;84(10):3666-3672.
- 1159 70. Antonio L, Wu FC, O'Neill TW, et al. Low Free Testosterone Is Associated with Hypogonadal Signs  
1160 and Symptoms in Men with Normal Total Testosterone. *J Clin Endocrinol Metab*. 2016;101(7):2647-  
1161 2657.
- 1162 71. Rastrelli G, O'Neill TW, Ahern T, et al. Symptomatic androgen deficiency develops only when both  
1163 total and free testosterone decline in obese men who may have incident biochemical secondary  
1164 hypogonadism: Prospective results from the EMAS. *Clinical endocrinology*. 2018;89(4):459-469.
- 1165 72. O'Connor DB, Lee DM, Corona G, et al. The relationships between sex hormones and sexual  
1166 function in middle-aged and older European men. *J Clin Endocrinol Metab*. 2011;96(10):E1577-  
1167 1587.
- 1168 73. Cawthon PM, Ensrud KE, Laughlin GA, et al. Sex hormones and frailty in older men: the  
1169 osteoporotic fractures in men (MrOS) study. *J Clin Endocrinol Metab*. 2009;94(10):3806-3815.
- 1170 74. Krasnoff JB, Basaria S, Pencina MJ, et al. Free testosterone levels are associated with mobility  
1171 limitation and physical performance in community-dwelling men: the Framingham Offspring Study.  
1172 *J Clin Endocrinol Metab*. 2010;95(6):2790-2799.
- 1173 75. Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the health  
1174 in men study. *J Clin Endocrinol Metab*. 2010;95(7):3165-3172.

- 1175 76. Swiecicka A, Eendebak R, Lunt M, et al. Reproductive Hormone Levels Predict Changes in Frailty  
1176 Status in Community-Dwelling Older Men: European Male Ageing Study Prospective Data. *J Clin*  
1177 *Endocrinol Metab.* 2018;103(2):701-709.
- 1178 77. Yeap BB, Almeida OP, Hyde Z, et al. Higher serum free testosterone is associated with better  
1179 cognitive function in older men, while total testosterone is not. The Health In Men Study. *Clinical*  
1180 *endocrinology.* 2008;68(3):404-412.
- 1181 78. Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L. Low free testosterone concentration as a  
1182 potentially treatable cause of depressive symptoms in older men. *Arch Gen Psychiatry.*  
1183 2008;65(3):283-289.
- 1184 79. Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD  
1185 and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res.* 2006;21(4):529-535.
- 1186 80. LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum testosterone, estradiol, and sex  
1187 hormone binding globulin levels on fracture risk in older men. *J Clin Endocrinol Metab.*  
1188 2009;94(9):3337-3346.
- 1189 81. Woods DR, Hill NE, Neely RDG, Talks KL, Heggie A, Quinton R. Hematopoiesis Shows Closer  
1190 Correlation with Calculated Free Testosterone in Men than Total Testosterone. *J Appl Lab Med.*  
1191 2017;1(4):441-444.
- 1192 82. Corona G, Torres LO, Maggi M. Testosterone Therapy: What We Have Learned From Trials. *J Sex*  
1193 *Med.* 2020;17(3):447-460.
- 1194 83. Llahana S. Testosterone Therapy in Adult Men with Hypogonadism. In: Llahana S, Follin C, Yedinak  
1195 C, Grossman A, eds. *Advanced Practice in Endocrinology Nursing.* Cham: Springer International  
1196 Publishing; 2019:885-902.
- 1197 84. Bhasin S, Jameson JL. Disorders of the testes and male reproductive system In: Jameson JL, ed.  
1198 *Harrison's Endocrinology* 4th Edition ed. New York: McGraw Hill Education; 2017:159 - 185.
- 1199 85. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in  
1200 hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center  
1201 Study. *J Clin Endocrinol Metab.* 2000;85(3):964-969.
- 1202 86. Cunningham G, Belkoff L, Brock G, et al. Efficacy and safety of a new topical testosterone  
1203 replacement gel therapy for the treatment of male hypogonadism. *Endocrine practice : official*  
1204 *journal of the American College of Endocrinology and the American Association of Clinical*  
1205 *Endocrinologists.* 2017;23(5):557-565.

- 1206 87. Spratt DI, Stewart II, Savage C, et al. Subcutaneous Injection of Testosterone Is an Effective and  
1207 Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender  
1208 Patients. *The Journal of Clinical Endocrinology & Metabolism*. 2017;102(7):2349-2355.
- 1209 88. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone  
1210 Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. *Sex Med*.  
1211 2015;3(4):269-279.
- 1212 89. Santhakumar A, Miller M, Quinton R. Pubertal induction in adult males with isolated  
1213 hypogonadotropic hypogonadism using long-acting intramuscular testosterone undecanoate 1-g  
1214 depot (Nebido). *Clinical endocrinology*. 2014;80(1):155-157.
- 1215 90. Pazderska A, Mamoojee Y, Artham S, et al. Safety and tolerability of one-year intramuscular  
1216 testosterone regime to induce puberty in older men with CHH. *Endocrine connections*.  
1217 2018;7(1):133-138.
- 1218 91. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate:  
1219 pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men  
1220 with hypogonadism. *J Clin Endocrinol Metab*. 2004;89(11):5429-5434.
- 1221 92. Minnemann T, Schubert M, Freude S, et al. Comparison of a new long-acting testosterone  
1222 undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male  
1223 hypogonadism. *Journal of endocrinological investigation*. 2008;31(8):718-723.
- 1224 93. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone  
1225 treatment and time span until maximum effects are achieved. *European journal of endocrinology /*  
1226 *European Federation of Endocrine Societies*. 2011;165(5):675-685.
- 1227 94. Coskuner ER, Ozkan B, Culha MG. Sexual Problems of Men With Androgenic Alopecia Treated With  
1228 5-Alpha Reductase Inhibitors. *Sexual Medicine Reviews*. 2019;7(2):277-282.
- 1229 95. Shin YS, Karna KK, Choi BR, Park JK. Finasteride and Erectile Dysfunction in Patients with Benign  
1230 Prostatic Hyperplasia or Male Androgenetic Alopecia. *World J Mens Health*. 2019;37(2):157-165.
- 1231 96. Pallotti F, Senofonte G, Pelloni M, et al. Androgenetic alopecia: effects of oral finasteride on  
1232 hormone profile, reproduction and sexual function. *Endocrine*. 2020;68(3):688-694.
- 1233 97. Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: An emerging clinical problem.  
1234 *Neurobiology of Stress*. 2020;12:100209.
- 1235 98. Pereira AFJR, Coelho TdA. Post-finasteride syndrome. *Anais Brasileiros de Dermatologia*.  
1236 2020;95(3):271-277.
- 1237 99. Gray SL, Semla TP. Post-finasteride syndrome. *BMJ (Clinical research ed)*. 2019;366:l5047.



- 1238 100. Zitzmann M. Effects of testosterone replacement and its pharmacogenetics on physical  
1239 performance and metabolism. *Asian J Androl.* 2008;10(3):364-372.
- 1240 101. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship.  
1241 *European journal of endocrinology / European Federation of Endocrine Societies.* 2006;155(6):773-  
1242 781.
- 1243 102. Dwyer AA, Tiemensma J, Quinton R, Pitteloud N, Morin D. Adherence to treatment in men with  
1244 hypogonadotrophic hypogonadism. *Clinical endocrinology.* 2017;86(3):377-383.
- 1245 103. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for  
1246 hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims  
1247 analysis. *The journal of sexual medicine.* 2013;10(5):1401.
- 1248 104. Donatucci C, Cui Z, Fang Y, Muram D. Long-term treatment patterns of testosterone replacement  
1249 medications. *The journal of sexual medicine.* 2014;11(8):2092.
- 1250 105. Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with  
1251 testosterone replacement therapies: the reasons behind the choices. *The journal of sexual*  
1252 *medicine.* 2014;11(2):553-562.
- 1253 106. Szeinbach SL, Seoane-Vazquez E, Summers KH. Development of a men's Preference for  
1254 Testosterone Replacement Therapy (P-TRT) instrument. *Patient preference and adherence.*  
1255 2012;6:631-641.
- 1256 107. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. *J Endocrinol.*  
1257 2013;217(3):R47-71.
- 1258 108. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of  
1259 testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab.*  
1260 2008;93(3):914-919.
- 1261 109. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor  
1262 density and aggregation responses. *Circulation.* 1995;91(11):2742-2747.
- 1263 110. Tsang S, Wong SS, Wu S, Kravtsov GM, Wong TM. Testosterone-augmented contractile responses  
1264 to alpha1- and beta1-adrenoceptor stimulation are associated with increased activities of RyR,  
1265 SERCA, and NCX in the heart. *Am J Physiol Cell Physiol.* 2009;296(4):C766-782.
- 1266 111. Schwartz JB, Volterrani M, Caminiti G, et al. Effects of testosterone on the Q-T interval in older men  
1267 and older women with chronic heart failure. *International journal of andrology.* 2011;34(5 Pt  
1268 2):e415-421.

1269 112. Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. *J Clin*  
1270 *Endocrinol Metab.* 2014;99(4):1357-1366.

1271 113. Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous Testosterone  
1272 Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. *J Sex Med.*  
1273 2018;15(9):1260-1271.

1274 114. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone  
1275 administration. *The New England journal of medicine.* 2010;363(2):109-122.

1276 115. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular  
1277 risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic  
1278 syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. *J Sex*  
1279 *Med.* 2010;7(10):3495-3503.

1280 116. Brock G, Heiselman D, Maggi M, et al. Effect of Testosterone Solution 2% on Testosterone  
1281 Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. *J*  
1282 *Urol.* 2016;195(3):699-705.

1283 117. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque  
1284 Volume in Older Men With Low Testosterone. *Jama.* 2017;317(7):708-716.

1285 118. Mohler ER, 3rd, Ellenberg SS, Lewis CE, et al. The Effect of Testosterone on Cardiovascular  
1286 Biomarkers in the Testosterone Trials. *J Clin Endocrinol Metab.* 2018;103(2):681-688.

1287 119. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among  
1288 men: a systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med.*  
1289 2013;11:108.

1290 120. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting  
1291 medications: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2014;13(10):1327-1351.

1292 121. Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of  
1293 testosterone administration: a systematic review and meta-analysis. *BMC Med.* 2014;12:211.

1294 122. Seftel AD, Kathrins M, Niederberger C. Critical Update of the 2010 Endocrine Society Clinical  
1295 Practice Guidelines for Male Hypogonadism: A Systematic Analysis. *Mayo Clin Proc.*  
1296 2015;90(8):1104-1115.

1297 123. FDA. FDA Drug Safety Communication: FDA cautions about using testosterone products for low  
1298 testosterone due to aging; requires labeling change to inform of possible increased risk of heart  
1299 attack and stroke with use. A US Federal Drugs Administration (FDA) drug safety communications

- 1300 announcement on 31st January 2014. Available on-line via:  
 1301 <https://www.fda.gov/media/91048/download> [Accessed 8th May 2021].
- 1302 124. EMA. European Medicines Agency EMA/706140/2014: No consistent evidence of an increased risk  
 1303 of heart problems with testosterone medicines. An EMA drug safety communications  
 1304 announcement on 21st November 2014. Available on-line via:  
 1305 [https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-no-](https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone_en.pdf)  
 1306 [consistent-evidence-increased-risk-heart-problems-testosterone\\_en.pdf](https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone_en.pdf) [Accessed 8th May 2021].
- 1307 125. Jayasena CN. NIHR HTA Testosterone Efficacy & Safety (TestES) Consortium: Investigating the  
 1308 effects of androgen replacement therapy. Multisite study funded by the National Institute of  
 1309 Healthcare Research Health Technology Assessment (NIHR HTA). On-line:  
 1310 [https://www.imperial.ac.uk/metabolism-digestion-reproduction/research/diabetes-endocrinology-](https://www.imperial.ac.uk/metabolism-digestion-reproduction/research/diabetes-endocrinology-metabolism/endocrinology-and-investigative-medicine/nihr-testosterone/)  
 1311 [metabolism/endocrinology-and-investigative-medicine/nihr-testosterone/](https://www.imperial.ac.uk/metabolism-digestion-reproduction/research/diabetes-endocrinology-metabolism/endocrinology-and-investigative-medicine/nihr-testosterone/) [Accessed 8th May  
 1312 2021]. In:Ongoing unpublished work.
- 1313 126. AbbVie. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the  
 1314 Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal  
 1315 Men (TRAVERSE). Ongoing unpublished clinical trial. On-line:  
 1316 <https://www.clinicaltrials.gov/ct2/show/NCT03518034> [Accessed 8th May 2021].
- 1317 127. Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in  
 1318 Transgender Persons: A Cohort Study. *Ann Intern Med.* 2018;169(4):205-213.
- 1319 128. Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. Occurrence of Acute  
 1320 Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. *Circulation.*  
 1321 2019;139(11):1461-1462.
- 1322 129. Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous  
 1323 Thromboembolism Among Men With and Without Hypogonadism. *JAMA Intern Med.*  
 1324 2020;180(2):190-197.
- 1325 130. Jick SS, Hagberg KW. The risk of adverse outcomes in association with use of testosterone products:  
 1326 a cohort study using the UK-based general practice research database. *Br J Clin Pharmacol.*  
 1327 2013;75(1):260-270.
- 1328 131. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on  
 1329 Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical  
 1330 Trial. *JAMA Intern Med.* 2017;177(4):471-479.
- 1331 132. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70(1):7-30.

1332 133. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the  
1333 saturation model and the limits of androgen-dependent growth. *Eur Urol.* 2009;55(2):310-320.

1334 134. Lenfant L, Leon P, Cancel-Tassin G, et al. Testosterone replacement therapy (TRT) and prostate  
1335 cancer: An updated systematic review with a focus on previous or active localized prostate cancer.  
1336 *Urol Oncol.* 2020;38(8):661-670.

1337 135. Santella C, Renoux C, Yin H, Yu OHY, Azoulay L. Testosterone Replacement Therapy and the Risk of  
1338 Prostate Cancer in Men With Late-Onset Hypogonadism. *Am J Epidemiol.* 2019;188(9):1666-1673.

1339 136. Kim M, Byun SS, Hong SK. Testosterone Replacement Therapy in Men with Untreated or Treated  
1340 Prostate Cancer: Do We Have Enough Evidences? *World J Mens Health.* 2020.

1341 137. Chambers TJ, Anderson RA. The impact of obesity on male fertility. *Hormones.* 2015;14(4):563-568.

1342 138. Roth MY, Page ST, Lin K, et al. Dose-dependent increase in intratesticular testosterone by very low-  
1343 dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. *J*  
1344 *Clin Endocrinol Metab.* 2010;95(8):3806-3813.

1345 139. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in  
1346 hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. *European journal*  
1347 *of endocrinology / European Federation of Endocrine Societies.* 2002;147(5):617-624.

1348 140. Vicari E, Mongioi A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces  
1349 spermatogenesis in men with isolated hypogonadotropic hypogonadism--long-term follow-up.  
1350 *International journal of andrology.* 1992;15(4):320-329.

1351 141. Dwyer AA, Sykiotis GP, Hayes FJ, et al. Trial of recombinant follicle-stimulating hormone  
1352 pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic  
1353 hypogonadism. *J Clin Endocrinol Metab.* 2013;98(11):E1790-1795.

1354 142. Nieschlag E, Bouloux PG, Stegmann BJ, et al. An open-label clinical trial to investigate the efficacy  
1355 and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic  
1356 hypogonadism. *Reprod Biol Endocrinol.* 2017;15(1):17.

1357 143. Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M. Testicular growth and spermatogenesis:  
1358 new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a  
1359 multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. *Clinical*  
1360 *endocrinology.* 2017;86(1):75-87.

1361 144. Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic  
1362 gonadotropin/human menopausal gonadotropin as effective treatment for men with

1363 hypogonadotropic hypogonadism: a review of 42 cases. *European journal of endocrinology /*  
1364 *European Federation of Endocrine Societies*. 1998;139(3):298-303.

1365 145. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis  
1366 and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of  
1367 fertility outcome. *J Clin Endocrinol Metab*. 2009;94(3):801-808.

1368 146. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to  
1369 identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism  
1370 treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.  
1371 *Fertil Steril*. 2009;92(2):594-604.